Video Abstract

Video Abstract

Close modal
OBJECTIVE

To test efficacy of a parent-delivered multidomain early intervention (Learning through Everyday Activities with Parents [LEAP-CP]) for infants with cerebral palsy (CP) compared with equal-dose of health advice (HA), on (1) infant development; and (2) caregiver mental health. It was hypothesized that infants receiving LEAP-CP would have better motor function, and caregivers better mental health.

METHODS

This was a multisite single-blind randomized control trial of infants aged 12 to 40 weeks corrected age (CA) at risk for CP (General Movements or Hammersmith Infant Neurologic Examination). Both LEAP-CP and HA groups received 15 fortnightly home-visits by a peer trainer. LEAP-CP is a multidomain active goal-directed intervention. HA is based on Key Family Practices, World Health Organization. Primary outcomes: (1) infants at 18 months CA: Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT mobility); and (2) caregiver: Depression Anxiety and Stress Scale.

RESULTS

Of eligible infants, 153 of 165 (92.7%) were recruited (86 males, mean age 7.1±2.7 months CA, Gross Motor Function Classification System at 18 m CA: I = 12, II = 25, III = 9, IV = 18, V = 32). Final data were available for 118 (77.1%). Primary (PEDI-CAT mobility mean difference = 0.8 (95% CI −1.9 to 3.6) P = .54) and secondary outcomes were similar between-groups. Modified-Intention-To-Treat analysis on n = 96 infants with confirmed CP showed Gross Motor Function Classification System I and IIs allocated to LEAP-CP had significantly better scores on PEDI-CAT mobility domain (mean difference 4.0 (95% CI = 1.4 to 6.5), P = .003) compared with HA.

CONCLUSIONS

Although there was no overall effect of LEAP-CP compared with dose-matched HA, LEAP-CP lead to superior improvements in motor skills in ambulant children with CP, consistent with what is known about targeted goal-directed training.

What’s Known on This Subject:

Randomized controlled trials of interventions for children with cerebral palsy (CP) in low- and middle-income countries (LMIC) have focused on children >12 months or included broader populations of “at risk” infants (preterm or neonatal encephalopathy).

What This Study Adds:

This randomized control trial tested peer-delivered early invention for infants with CP in LMICs. There were similar infant motor and caregiver mental health outcomes between intervention and active control. Infant motor was better in infants with ambulatory CP receiving intervention.

Cerebral Palsy (CP) is a group of conditions resulting from a lesion to the developing brain.1  Although the timing frequently precedes or is around the time of birth, targeted interventions for CP are regularly not initiated until after the child’s second birthday, at the time of diagnosis.2  The CP International Clinical Practice Guideline for Early Intervention for infants at risk for CP advocates fast-tracking to interventions that build parental capacity for attachment, include parent-lead goal setting, and active task-specific training.3  Children with CP living in low- and middle-income countries (LMICs) are among the most disadvantaged globally, with 80% of cases worldwide.4  In this context there is a greater prevalence of more complex clinical profiles, with poorer motor function, higher rates of dyskinesia, and a more complex array of comorbidities.5,6  This is exacerbated by later diagnosis, often at school age5 ; and subsequently numerous barriers (geographical, economic, informational and attitudinal) to access targeted active interventions.7,8  Allied health services are often unidisciplinary, available only in tertiary centers, and not based on recommendations of the CP-International Clinical Practice Guideline.8  Most randomized controlled trials of interventions for children with CP in LMICs have focused on children >12 months,9 14  or include broader populations of “at risk” infants (preterm,15 22  or neonatal encephalopathy).23,24 

The Learning through Everyday Activities with Parents-CP (LEAP-CP) program (Learning through Everyday Activities with Parents for infants at risk for CP) is a novel early intervention targeted for infants with CP and is designed to specifically address common service access barriers in a LMIC. It is delivered early (<12 months) by peers in the home and includes targeted goal directed training (motor, upper limb, communication, vision, and feeding or nutrition) with cognitive learning games and support for the caregiver’s mental health. This study aimed to determine whether LEAP-CP was effective for improving infant development and/or caregiver mental health for infants at high risk of CP in LMICs. It was hypothesized that infants and their caregivers receiving LEAP-CP, compared with Health Advice (HA), would have better scores on the Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) mobility domain and Depression Anxiety and Stress Scale (DASS).

This single-blind randomized control trial (RCT) of LEAP-CP was conducted in West Bengal, India from March 2017 to November 2020.25  Ethics approval was gained through the Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee (HREC/16/QRCH/214), The University of Queensland Medical Research Ethics Committee (2016001073), Apollo Gleneagles Hospital Kolkata Institutional Ethics Committee (IEC/2016/12/35), and the Dr BC Roy Postgraduate Institute Institutional Ethics Committee (BCH/ME/PR/54). All families gave written informed consent to participate.

Infants aged 12 to 40 weeks corrected age (CA) with birth or infant identifiable risk factors who were screened as “high risk of CP” and resided in a study geographical area (2 rural districts, with community and tertiary hospital referrals; 1 urban informal settlement or slum with community referral) were referred to the trial.25  CP risk was determined using the General Movements Assessment or Hammersmith Infant Neurologic Examination (HINE). Infants were defined at risk if General Movements Assessment at 12 to 17 weeks CA was classified as absent or abnormal fidgety, or HINE was less than 56, 59, and 62 at 3, 6, and 9 months CA (respectively).26  Infants with known or suspected congenital or chromosomal abnormalities (based on medical records) that were likely to affect their neurodevelopmental outcome, diagnosed with neurodegenerative conditions, or considered medically fragile (determined by primary physician) were excluded.

Infants with birth or infant detectable risk factors were identified in the community through field visits by community disability workers (CDWs, n = 11) who were responsible for both participant identification and delivery of the intervention with support from the child-health site coordinator. CDWs identified potential participants using multiple identification strategies, including expansion of existing services (routine immunization clinics, primary health centers, community antenatal or primary care); conducting community activities or education alongside recruitment; and household screening. Infants in the hospital were identified by discharge record review and screened at Special Care Nursery follow-up clinics.

After baseline assessment, an independent researcher randomized infants to LEAP-CP or HA using simple randomization based on computer generated sequences, stored centrally (REDCap v8.0.2 database, Vanderbilt University, USA 2009). Twins were randomized as a single family unit. The intervention and comparator were labeled with neutral terms (“Play Program” and “Health Program”) to ensure caregivers receiving the intervention and CDWs administering the intervention did not know which intervention was active versus comparison.

Infants received their assigned intervention from enrollment for 15 fortnightly visits or until they reached 18 months CA (whichever occurred first). Infants from both study arms were visited in the home by a CDW and were encouraged to access medical or allied health services available in their community.25 

LEAP-CP

LEAP-CP is a peer-delivered multidomain intervention provided in the home, contextualized for LMICs.25  It is based on principles of active goal-directed training (parent-identified goals); responsive parenting, building caregiver capacity, and caregiver mental health grounded in Acceptance Commitment Therapy (parent education); and environmental enrichment, including cognition (CP Learning Games).27,28  CDWs, who were women from the local community, provided support to significant family members, coached goal-directed tasks, and engaged in collaborative education and decision making. CDWs were supported through fortnightly training by a treatment coordinator (child health professional).

HA

HA was based on the World Health Organization’s Integrated Management of Childhood Illness Key Family Practices (breastfeeding, complementary nutrition, hygiene practices, vaccinations, management of illness, maternal mental health).25  This included clinical signs indicating referral to existing health services.

Outcomes at enrolment and study completion (18 months CA) were conducted by a masked assessor (S.C.) trained by lead authors (K.B. and R.B.).25 

Primary Infant Outcome Measure

Infant function was assessed using the PEDI-CAT, a parent-reported measure including self-care, mobility, and social function.29  The mobility domain was selected as the primary infant outcome.

Primary Caregiver Outcome Measure

Caregiver mental health symptoms were assessed using the DASS, a self-reported norm-referenced measure.30 

Secondary Outcome Measures25 

Secondary infant developmental outcomes included goal attainment (Canadian Occupational Performance Measure31 ), motor (Peabody Developmental Motor Scales – second edition (PDMS-2)32 ), cognition or language (Bayley Scales of Infant Development — third edition (BSID-III)33 ), vision (Near Detection Scale34 ), nutritional status (length, weight, and BMI Z-scores35 ), neurologic status (HINE26 ); home environment (Home Observation for Measurement of the Environment (HOME) Inventory36 ); and caregiver outcomes (Parenting Sense of Competence Scale [PSOC]37 ).

Information collected at enrollment included caregiver-reported birth and developmental history,6,38  family economic status (Poverty Measurement Tool [PMT])39  and Social Risk Index [SRI]).40  At 18-months CA, a differential diagnosis of “CP and alike conditions” (motor conditions of presumed central origin) was determined41,42 ; and classification of the Gross Motor Function Classification System (GMFCS) (<2 year age band)43 ; motor type or distribution.44  These were classified from videoed clinical assessment by an Australian pediatrician (>25 years experience) masked to clinical history.

The PEDI-CAT mobility domain can detect a 1 SD change after ≥3 months of physiotherapy in children <3 years.45  With 64 children per group, a medium effect size ≥0.5 SD between-groups is detectable (α = .05, β = .8); total n = 142 (10% attrition).25 

Generalized linear models with Gaussian families and identity links were constructed to compare between-group differences on primary (PEDI-CAT mobility domain scaled score, DASS total score) and secondary outcomes. Models were adjusted for baseline scores. Missing data were not imputed, and a complete-case analysis was performed. Analyses were conducted following the Intention-To-Treat (ITT) principle. Analyses were repeated using a modified-ITT (mITT) sample that excluded participants with typical development at 18 months CA. Secondary analyses tested between-group and within-group pre to post differences stratified by GMFCS (I–II, III–IV, and V). The stratification by GMFCS differs from the a priori analysis plan to stratify according to the covariable of neurologic severity (binary HINE score < 40). As we had incomplete data for the HINE at 18 months, and HINE was being used as a proxy for gross motor function (HINE < 40 indicates nonambulatory CP), we opted to use the GMFCS classification. Finally, the association between participant characteristics and outcome measures was explored. Formal adjustment for multiplicity was not performed, and these findings should be interpreted cautiously. All analyses were undertaken using Stata V.13.1 (Stata statistical software, College Station, TX, USA). Significance was set at P < .05.

There were 165 infants screened as “high risk of CP” and invited to participate (Fig 1). 153 infants (93%) were randomized (LEAP-CP n = 77; HA n = 76; 86 males; mean age 7.1±2.7 months CA; Table 1). Three sets of twins participated (n = 2 LEAP-CP, n = 1 HA). There were 32 infants lost to follow-up and 3 discontinued (LEAP-CP n = 18, retention 77%; HA n = 17, retention 78%; Fig 1). No significant differences were found between participants completing and dropouts for sex, age, or HINE score at baseline.

FIGURE 1

CONSORT flow of participants through trial.

FIGURE 1

CONSORT flow of participants through trial.

Close modal
TABLE 1

Demographics and Baseline Characteristics of Children Participating in LEAP-CP Trial

Primary Sample (n = 153)
LEAP-CP (n = 77)Health Advice(n = 76)
Sex (n, % males) 47 (61.0) 39 (51.3) 
Age (months), mean (SD) 7.1 (2.8) 7.0 (2.5) 
Religion   
 Hindu 29 (37.7) 34 (46.6) 
 Muslim 47 (61. 0) 38 (52.1) 
 Christian 1 (1.3) 1 (1.4) 
Site (n, %)   
 Asha Bhavan Centre 23 (29.9) 21 (27.6) 
 Dr BC Roy Postgraduate Centre for Pediatric Sciences 43 (58.4) 40 (52.6) 
 Child In Need Institute 11 (14.3) 15 (19.7) 
Motor severity (HINE), n = 90   
 Total optimality score (mean, SD) 39.6 (16.1) 36.2 (15.0) 
 Optimality score >60, n (%) 3 (6.4) 0 (0.0) 
 Optimality score 40–60, n (%) 25 (53.2) 21 (48.8) 
 Optimality score <40, n (%) 19 (40.4) 22 (51.2) 
Social risk indexd (n, % high risk) 71 (94.7) 69 (90.8) 
Poverty Measurement Tool total score: mean (SD)a 36.8 (6.5) 35.7 (5.5) 
 Well off 29 (37.7) 33 (44.6) 
 Moderately well off 17 (22.1) 19 (25.7) 
 Not so well off 12 (15.6) 7 (9.5) 
 Poor 8 (10.4) 9 (12.2) 
 Very poor 11 (14.3) 6 (8.1) 
Primary caregiver age (years) 23.9 (6.0) 22.9 (4.6) 
Primary caregiver education   
 No formal schooling 8 (10.4) 3 (4.1) 
 Primary 39 (50.7) 41 (56.2) 
 Class 10 15 (19.5) 13 (17.8) 
 High school certificate 9 (11.7) 11 (15.1) 
 Tertiary 6 (7.8) 5 (6.9) 
Comorbidities   
 Epilepsy 24 (31.6) 25 (34.7) 
 Vision 32 (41.6) 23 (31.5) 
 Hearing 25 (32.5) 20 (27.4) 
 Cognition 33 (43.4) 32 (44.4) 
Percentage days sickd (mean, SD) 18.3 (28.0) 16.4 (28.4) 
GMFCS (18 mo CA)b   
 I 8 (16.0) 4 (8.7) 
 II 10 (20.0) 15 (32.6) 
 III 6 (12.0) 3 (6.5) 
 IV 10 (20.0) 8 (17.4) 
 V 16 (32.0) 16 (34.8) 
Primary motor type (18 mo CA)c   
 Unilateral spasticity 2 (4.8) 2 (5.4) 
 Bilateral spasticity (2 limb) 0 (0.0) 1 (2.7) 
 Bilateral spasticity (3+ limbs) 13 (31.0) 10 (27.0) 
 Dyskinetic 6 (14.3) 10 (27.0) 
 Mixed spasticity or dystonia 9 (21.4) 7 (18.9) 
 Hypotonic 8 (19.1) 4 (10.8) 
 Ataxic 4 (9.5) 3 (8.1) 
Primary Sample (n = 153)
LEAP-CP (n = 77)Health Advice(n = 76)
Sex (n, % males) 47 (61.0) 39 (51.3) 
Age (months), mean (SD) 7.1 (2.8) 7.0 (2.5) 
Religion   
 Hindu 29 (37.7) 34 (46.6) 
 Muslim 47 (61. 0) 38 (52.1) 
 Christian 1 (1.3) 1 (1.4) 
Site (n, %)   
 Asha Bhavan Centre 23 (29.9) 21 (27.6) 
 Dr BC Roy Postgraduate Centre for Pediatric Sciences 43 (58.4) 40 (52.6) 
 Child In Need Institute 11 (14.3) 15 (19.7) 
Motor severity (HINE), n = 90   
 Total optimality score (mean, SD) 39.6 (16.1) 36.2 (15.0) 
 Optimality score >60, n (%) 3 (6.4) 0 (0.0) 
 Optimality score 40–60, n (%) 25 (53.2) 21 (48.8) 
 Optimality score <40, n (%) 19 (40.4) 22 (51.2) 
Social risk indexd (n, % high risk) 71 (94.7) 69 (90.8) 
Poverty Measurement Tool total score: mean (SD)a 36.8 (6.5) 35.7 (5.5) 
 Well off 29 (37.7) 33 (44.6) 
 Moderately well off 17 (22.1) 19 (25.7) 
 Not so well off 12 (15.6) 7 (9.5) 
 Poor 8 (10.4) 9 (12.2) 
 Very poor 11 (14.3) 6 (8.1) 
Primary caregiver age (years) 23.9 (6.0) 22.9 (4.6) 
Primary caregiver education   
 No formal schooling 8 (10.4) 3 (4.1) 
 Primary 39 (50.7) 41 (56.2) 
 Class 10 15 (19.5) 13 (17.8) 
 High school certificate 9 (11.7) 11 (15.1) 
 Tertiary 6 (7.8) 5 (6.9) 
Comorbidities   
 Epilepsy 24 (31.6) 25 (34.7) 
 Vision 32 (41.6) 23 (31.5) 
 Hearing 25 (32.5) 20 (27.4) 
 Cognition 33 (43.4) 32 (44.4) 
Percentage days sickd (mean, SD) 18.3 (28.0) 16.4 (28.4) 
GMFCS (18 mo CA)b   
 I 8 (16.0) 4 (8.7) 
 II 10 (20.0) 15 (32.6) 
 III 6 (12.0) 3 (6.5) 
 IV 10 (20.0) 8 (17.4) 
 V 16 (32.0) 16 (34.8) 
Primary motor type (18 mo CA)c   
 Unilateral spasticity 2 (4.8) 2 (5.4) 
 Bilateral spasticity (2 limb) 0 (0.0) 1 (2.7) 
 Bilateral spasticity (3+ limbs) 13 (31.0) 10 (27.0) 
 Dyskinetic 6 (14.3) 10 (27.0) 
 Mixed spasticity or dystonia 9 (21.4) 7 (18.9) 
 Hypotonic 8 (19.1) 4 (10.8) 
 Ataxic 4 (9.5) 3 (8.1) 

SRI out of 5 items only.

a

Categorized sores indicate those “well off” with basic daily needs met, and all other categories indicating unmet daily needs.

b

mITT excludes children with typical outcomes at 18 mo CA, n = 96.

c

Motor type only available for n = 79 with confirmed CP.

d

Percentage days sick based on age in days.

Demographic and baseline characteristics are presented in Tables 1 and 2. Groups were generally similar, although there was a greater nonsignificant proportion of families in LEAP-CP compared with HA who were (1) “very poor” families (14% vs 8%), (2) primary caregivers with no formal schooling (10% vs 4%), (3) infants classified as severe-profound undernutrition (36% vs 22%), and (4) infants with poor vision (42% vs 32%).

TABLE 2

Comparison of Baseline Evaluation for LEAP-CP Trial Participants (n = 153)

LEAP-CP Intervention, n = 77Health Advice, n = 76
PEDI-CAT SS (mean, SD)   
 Mobilityc 42.3 (4.9) 42.3 (6.0) 
 Daily activities 33.1 (4.0) 33.4 (4.0) 
 Social-communication 36.4 (6.9) 37.9 (6.8) 
DASS (mean, SD) 23.9 (20.1) 25.0 (21.8) 
 Overallc   
 Depression 7.7 (8.4) 7.9 (8.5) 
 Anxiety 5.7 (7.0) 6.5 (7.1) 
 Stress 10.4 (7.9) 10.6 (8.4) 
PDMS-2 (mean, SD)   
 Total Motor Quotient 74.1 (23.3) 72.9 (22.8) 
 Total raw score 57.5 (47.5) 57.3 (46.6) 
 Gross motor raw score 33.3 (26.7) 32.0 (25.0) 
 Fine motor raw score 24.2 (21.9) 25.3 (24.0) 
BSID-III (mean, SD)   
 Cognitive composite score 70.8 (23.4) 74.0 (25.6) 
 Cognition raw score 13.3 (11.7) 15.1 (12.3) 
 Language composite score 64.6 (19.8) 67.1 (19.4) 
 Receptive language raw score 5.1 (3.3) 5.5 (3.4) 
 Expressive language raw score 4.0 (2.9) 4.2 (2.8) 
HINE (mean, SD)a 45.0 (18.4) 43.9 (18.0) 
COPM (mean, SD)b   
 Performance 2.3 (1.4) 2.6 (1.2) 
 Satisfaction 2.4 (1.6) 2.7 (1.5) 
NVD (mean, SD) 4.9 (2.0) 4.9 (1.9) 
HOME (mean, SD) 25.0 (5.5) 26.5 (4.9) 
Anthropometry (mean, SD)   
 Length z-score −1.9 (2.0) −1.5 (2.0) 
 Wt z-score −2.5 (1.7) −2.0 (1.8) 
 BMI z-score −1.9 (1.8) −1.5 (1.9) 
Undernutrition length (n, %)   
 None (>−2 SD) 38 (49.4) 43 (58.9) 
 Mild-moderate (<−2 SD) 18 (23.4) 16 (21.9) 
 Severe-profound (<−3 SD) 21 (27.3) 14 (19.2) 
Undernutrition wt (n, %)   
 None (>−2SD) 35 (45.5) 41 (56.2) 
 Mild-moderate (<−2 SD) 14 (18.2) 16 (21.9) 
 Severe-profound (<−3 SD) 28 (36.4) 16 (21.9) 
Undernutrition BMI (n, %)   
 None (>−2SD) 43 (45.5) 49 (56.2) 
 Mild-moderate (<−2 SD) 16 (18.2) 8 (21.9) 
 Severe-profound (<−3 SD) 18 (36.4) 16 (21.9) 
PSOC (mean, SD) 64.2 (8.8) 65.6 (10.3) 
LEAP-CP Intervention, n = 77Health Advice, n = 76
PEDI-CAT SS (mean, SD)   
 Mobilityc 42.3 (4.9) 42.3 (6.0) 
 Daily activities 33.1 (4.0) 33.4 (4.0) 
 Social-communication 36.4 (6.9) 37.9 (6.8) 
DASS (mean, SD) 23.9 (20.1) 25.0 (21.8) 
 Overallc   
 Depression 7.7 (8.4) 7.9 (8.5) 
 Anxiety 5.7 (7.0) 6.5 (7.1) 
 Stress 10.4 (7.9) 10.6 (8.4) 
PDMS-2 (mean, SD)   
 Total Motor Quotient 74.1 (23.3) 72.9 (22.8) 
 Total raw score 57.5 (47.5) 57.3 (46.6) 
 Gross motor raw score 33.3 (26.7) 32.0 (25.0) 
 Fine motor raw score 24.2 (21.9) 25.3 (24.0) 
BSID-III (mean, SD)   
 Cognitive composite score 70.8 (23.4) 74.0 (25.6) 
 Cognition raw score 13.3 (11.7) 15.1 (12.3) 
 Language composite score 64.6 (19.8) 67.1 (19.4) 
 Receptive language raw score 5.1 (3.3) 5.5 (3.4) 
 Expressive language raw score 4.0 (2.9) 4.2 (2.8) 
HINE (mean, SD)a 45.0 (18.4) 43.9 (18.0) 
COPM (mean, SD)b   
 Performance 2.3 (1.4) 2.6 (1.2) 
 Satisfaction 2.4 (1.6) 2.7 (1.5) 
NVD (mean, SD) 4.9 (2.0) 4.9 (1.9) 
HOME (mean, SD) 25.0 (5.5) 26.5 (4.9) 
Anthropometry (mean, SD)   
 Length z-score −1.9 (2.0) −1.5 (2.0) 
 Wt z-score −2.5 (1.7) −2.0 (1.8) 
 BMI z-score −1.9 (1.8) −1.5 (1.9) 
Undernutrition length (n, %)   
 None (>−2 SD) 38 (49.4) 43 (58.9) 
 Mild-moderate (<−2 SD) 18 (23.4) 16 (21.9) 
 Severe-profound (<−3 SD) 21 (27.3) 14 (19.2) 
Undernutrition wt (n, %)   
 None (>−2SD) 35 (45.5) 41 (56.2) 
 Mild-moderate (<−2 SD) 14 (18.2) 16 (21.9) 
 Severe-profound (<−3 SD) 28 (36.4) 16 (21.9) 
Undernutrition BMI (n, %)   
 None (>−2SD) 43 (45.5) 49 (56.2) 
 Mild-moderate (<−2 SD) 16 (18.2) 8 (21.9) 
 Severe-profound (<−3 SD) 18 (36.4) 16 (21.9) 
PSOC (mean, SD) 64.2 (8.8) 65.6 (10.3) 

COPM, Canadian Occupational Performance Measure; NVD, Near Vision Detection; SS, Scaled Score.

a

n = 26 (17%) missing HINE baseline.

b

n = 15 (10%) missing COPM baseline as withdrew or deceased before goal setting.

c

Primary infant and caregiver outcomes.

Families completed a median interquartile range of 15 (0) visits over a mean duration of 11.6 months (LEAP-CP = 15 [0]; HA = 15 [0]). In the LEAP-CP and HA groups, 75% and 82% (respectively) completed ≥12 visits (93% and 92% with final outcome data, respectively). Three participants were >50 weeks CA when screened because of misreported age when eligibility was confirmed.

Primary Outcomes

At study completion, infant motor function (PEDI-CAT mean difference [MD] = 0.8 [95% confidence interval (CI) −1.9 to 3.6], P = .54) and caregiver mental health (DASS MD = 0.4 [95% CI −4.9 to 5.6], P = .90) did not differ significantly between-groups (Table 3).

TABLE 3

Comparison of Final Outcomes for LEAP-CP Trial Participants (n = 118)

LEAP-CP Intervention, N = 59Health Advice, N = 59Mean Difference (95% CI), P*
PEDI-CAT SS (mean, SD)a    
 Mobility 49.3 (8.3) 48.8 (8.7) 0.8 (−1.9 to 3.6), .54 
 Daily activities 39.4 (5.1) 39.6 (5.5) −0.2 (−2.1 to 1.6), .80 
 Social-communication 44.6 (8.5) 45.5 (8.3) −0.4 (−3.0 to 2.3), 0.79 
DASS (mean, SD)a    
 Overall 13.4 (14.9) 13.0 (16.0) 0.4 (−4.9 to 5.6), .90 
 Depression 4.9 (6.1) 4.6 (6.1) 0.2 (−1.9 to 2.4), .82 
 Anxiety 2.5 (3.4) 2.9 (4.8) −0.3 (−1.7 to 1.2), .70 
 Stress 6.0 (6.8) 5.7 (7.6) 0.4 (−2.1 to 2.8), .78 
PDMS-2 (mean, SD)    
 Total motor quotient 68.4 (25.6) 68.2 (25.0) −2.5 (−7.8 to −2.8), .35 
 Total raw score 147.6 (101.0) 145.3 (103.1) −2.6 (−29.7 to 24.6), .85 
 Gross motor raw score 77.1 (58.9) 76.4 (55.6) −3.8 (−18.2 to 10.7), .61 
 Fine motor raw score 70.5 (48.7) 68.9 (50.3) 1.3 (−12.5 to 15.1), .85 
BSID-III (mean, SD)    
 Cognition standard score 72.9 (22.8) 74.9 (21.2) −0.3 (−6.5 to 5.9), .92 
 Cognition raw score 31.3 (20.2) 31.4 (22.4) 1.6 (−3.7 to 7.0), .54 
 Language standard score 61.8 (16.4) 61.4 (14.1) 1.5 (−2.4 to 5.4), .46 
 Receptive language raw score 10.4 (6.0) 10.9 (6.4) −0.3 (−2.0 to 1.3), .70 
 Expressive language raw score 7.6 (5.3) 7.7 (5.5) 0.3 (−1.1 to 1.6), .71 
HINE score (n = 66) (mean, SD) 58.2 (27.7) 55.1 (21.8) 4.7 (−2.8 to 12.2), .21 
COPM (mean, SD)    
 Performance 6.8 (2.6) 7.0 (2.6) −0.1 (−0.9 to 0.8), .91 
 Satisfaction 7.0 (2.7) 7.1 (2.6) 0.1 (−0.8 to 1.0), .90 
NVDS (mean, SD) 5.9 (1.9) 5.8 (1.8) 0.1 (−0.4 to 0.5), .80 
HOME (mean, SD) 27.2 (4.6) 28.5 (4.5) −0.6 (−2.0 to 0.8), .39 
Anthropometry (mean, SD)    
 Length z score −2.2 (1.8) −1.5 (1.8) −0.5 (−1.2 to 0.1), .08 
 Wt z score −1.9 (1.8) −1.6 (1.3) 0.1 (−0.4 to 0.6), .75 
 BMI z score −1.1 (2.2) −0.9 (1.9) 0.2 (−0.3 to 0.8), .37 
Undernutrition length (n, %)   OR# 1.6 (0.8 to 3.3), .19 
 None (>−2 SD) 26 (44.1) 35 (59.3)  
 Mild-moderate (<−2 SD) 18 (30.5) 14 (23.7)  
 Severe-profound (<−3 SD) 15 (25.4) 10 (17.0)  
Undernutrition wt (n, %)   OR# 0.9 (0.4 to 1.9), .78 
 None (>−2 SD) 34 (59.3) 34 (57.6)  
 Mild-moderate (<−2 SD) 10 (17.0) 18 (30.5)  
 Severe-profound (<−3 SD) 14 (23.7) 7 (11.9)  
Undernutrition BMI (n, %)   OR# 0.7 (0.2 to 1.8), .44 
 None (>−2SD) 43 (72.8) 44 (74.6)  
 Mild-moderate (<−2 SD) 9 (15.3) 5 (8.5)  
 Severe-profound (<−3 SD) 7 (11.9) 10 (17.0)  
PSOC (mean, SD) 71.7 (11.0) 72.2 (11.0) 0.2 (−3.3 to 3.7), .93 
Mortality (n, %) 7 (9.1) 2 (2.6) OR 3.7 (0.7 to 18.3), .11 
LEAP-CP Intervention, N = 59Health Advice, N = 59Mean Difference (95% CI), P*
PEDI-CAT SS (mean, SD)a    
 Mobility 49.3 (8.3) 48.8 (8.7) 0.8 (−1.9 to 3.6), .54 
 Daily activities 39.4 (5.1) 39.6 (5.5) −0.2 (−2.1 to 1.6), .80 
 Social-communication 44.6 (8.5) 45.5 (8.3) −0.4 (−3.0 to 2.3), 0.79 
DASS (mean, SD)a    
 Overall 13.4 (14.9) 13.0 (16.0) 0.4 (−4.9 to 5.6), .90 
 Depression 4.9 (6.1) 4.6 (6.1) 0.2 (−1.9 to 2.4), .82 
 Anxiety 2.5 (3.4) 2.9 (4.8) −0.3 (−1.7 to 1.2), .70 
 Stress 6.0 (6.8) 5.7 (7.6) 0.4 (−2.1 to 2.8), .78 
PDMS-2 (mean, SD)    
 Total motor quotient 68.4 (25.6) 68.2 (25.0) −2.5 (−7.8 to −2.8), .35 
 Total raw score 147.6 (101.0) 145.3 (103.1) −2.6 (−29.7 to 24.6), .85 
 Gross motor raw score 77.1 (58.9) 76.4 (55.6) −3.8 (−18.2 to 10.7), .61 
 Fine motor raw score 70.5 (48.7) 68.9 (50.3) 1.3 (−12.5 to 15.1), .85 
BSID-III (mean, SD)    
 Cognition standard score 72.9 (22.8) 74.9 (21.2) −0.3 (−6.5 to 5.9), .92 
 Cognition raw score 31.3 (20.2) 31.4 (22.4) 1.6 (−3.7 to 7.0), .54 
 Language standard score 61.8 (16.4) 61.4 (14.1) 1.5 (−2.4 to 5.4), .46 
 Receptive language raw score 10.4 (6.0) 10.9 (6.4) −0.3 (−2.0 to 1.3), .70 
 Expressive language raw score 7.6 (5.3) 7.7 (5.5) 0.3 (−1.1 to 1.6), .71 
HINE score (n = 66) (mean, SD) 58.2 (27.7) 55.1 (21.8) 4.7 (−2.8 to 12.2), .21 
COPM (mean, SD)    
 Performance 6.8 (2.6) 7.0 (2.6) −0.1 (−0.9 to 0.8), .91 
 Satisfaction 7.0 (2.7) 7.1 (2.6) 0.1 (−0.8 to 1.0), .90 
NVDS (mean, SD) 5.9 (1.9) 5.8 (1.8) 0.1 (−0.4 to 0.5), .80 
HOME (mean, SD) 27.2 (4.6) 28.5 (4.5) −0.6 (−2.0 to 0.8), .39 
Anthropometry (mean, SD)    
 Length z score −2.2 (1.8) −1.5 (1.8) −0.5 (−1.2 to 0.1), .08 
 Wt z score −1.9 (1.8) −1.6 (1.3) 0.1 (−0.4 to 0.6), .75 
 BMI z score −1.1 (2.2) −0.9 (1.9) 0.2 (−0.3 to 0.8), .37 
Undernutrition length (n, %)   OR# 1.6 (0.8 to 3.3), .19 
 None (>−2 SD) 26 (44.1) 35 (59.3)  
 Mild-moderate (<−2 SD) 18 (30.5) 14 (23.7)  
 Severe-profound (<−3 SD) 15 (25.4) 10 (17.0)  
Undernutrition wt (n, %)   OR# 0.9 (0.4 to 1.9), .78 
 None (>−2 SD) 34 (59.3) 34 (57.6)  
 Mild-moderate (<−2 SD) 10 (17.0) 18 (30.5)  
 Severe-profound (<−3 SD) 14 (23.7) 7 (11.9)  
Undernutrition BMI (n, %)   OR# 0.7 (0.2 to 1.8), .44 
 None (>−2SD) 43 (72.8) 44 (74.6)  
 Mild-moderate (<−2 SD) 9 (15.3) 5 (8.5)  
 Severe-profound (<−3 SD) 7 (11.9) 10 (17.0)  
PSOC (mean, SD) 71.7 (11.0) 72.2 (11.0) 0.2 (−3.3 to 3.7), .93 
Mortality (n, %) 7 (9.1) 2 (2.6) OR 3.7 (0.7 to 18.3), .11 

n = 31 (26%) participants accessed physiotherapy in the previous 12 mo (n = 14 LEAP, n = 17 HA; intervention type included stretching (n = 4); NDT (n = 10); positioning (n = 28); goal-directed (n = 4); mean number of appointments = 18.5 (SD = 18.9, range = 1–70), mean appointment duration 19.1 min (SD = 9.5, range 10–30 min). COPM, Canadian Occupational Performance Measure; NVD, Near Vision Detection; OR#, indicates differences between proportion across classifications in ordered logistic regression; SS, scaled score.

a

Primary infant and caregiver outcomes.

* Adjusted for baseline scores.

Secondary Outcomes

The secondary outcomes of infant function, motor, cognition, language, goal-attainment, vision, neurologic status, home environment, nutritional status, and parenting competence did not differ significantly between-groups (Table 3).

Outcomes for Children With CP and Alike Conditions

There were 96 infants diagnosed as having CP and alike conditions who were included in mITT analyses (Table 4). Overall, only length Z-scores showed statistically significant between-group differences, which favored HA (MD −0.7 [95% CI −1.4 to 0.0], P = .05). When stratified for GMFCS, children classified GMFCS I or II in the LEAP-CP group scored better than HA on the PEDI-CAT mobility domain (MD = 4.0 [95% CI 1.4 to 6.5], P = .003) and the HINE (MD = 5.5 95% CI = 0.0 to 11.1], P = .05).

TABLE 4

Modified Intention to Treat for LEAP-CP Trial Participants: Comparison of Within-group and Between-group Differences for Participants With Confirmed Cerebral Palsy and Alike Conditions, Overall and According to Functional Severity on GMFCS (n = 96)

LEAP-CP, n = 50Health Advice n = 46Adjusted Between-group
Baseline Mean Score (SD)Final Mean Score (SD)Pre to Post Mean Difference (SD), PBaseline Mean Score (SD)Final Mean Score (SD)Pre to Post Mean Difference (SD), PFinal Outcome Adj Mean Difference (95% CI), P
PEDI-CAT mobility (SS)a        
 Overall 42.7 (5.1) 48.4 (8.2) 5.7 (6.5), <.001 33.5 (3.9) 38.0 (5.2) 4.5 (5.5), <.001 1.9 (−0.8 to 4.6), .16 
 GMFCS I–II 46.4 (4.1) 56.3 (3.8) 9.9 (5.5), <.001 45.4 (3.2) 52.4 (3.3) 7.0 (4.5), <.001 4.0 (1.4 to 6.5), .003 
 GMFCS III–IV 41.9 (5.6) 48.3 (5.6) 6.4 (6.2), <.001 43.8 (3.2) 48.3 (8.6) 4.5 (7.5), .06 1.1 (−4.2 to 6.5), .67 
 GMFCS V 39.2 (3.3) 39.6 (3.6) 0.4 (3.7), .69 38.1 (5.2) 38.1 (3.4) 0.1 (6.3), .97 1.4 (−1.2 to 4.0), .29 
PEDI-CAT DA (SS)        
 Overall 33.8 (4.4) 38.7 (5.0) 4.9 (5.1), <.001 33.5 (3.9) 38.0 (5.2) 4.5 (5.5), <.001 0.6 (−1.3 to 2.6), .52 
 GMFCS I–II 35.7 (5.4) 42.4 (4.4) 6.7 (6.6), <.001 34.5 (4.1) 42.1 (3.9) 7.6 (5.0), <.001 0.1 (−2.8 to 3.0), .93 
 GMFCS III–IV 33.9 (3.9) 39.4 (3.9) 5.6 (3.6), <.001 34.2 (4.7) 38.5 (4.8) 4.3 (6.7), .05 1.0 (−2.3 to 4.3), .55 
 GMFCS V 31.5 (2.1) 33.9 (1.8) 2.4 (2.4), .001 31.8 (2.6) 33.1 (1.3) 1.3 (2.7), .06 0.8 (−0.3 to 1.9), .15 
PEDI-CAT SC (SS)        
 Overall 37.3 (7.2) 43.8 (8.6) 6.5 (7.9), <.001 36.5 (6.8) 43.0 (7.8) 6.5 (6.3), <.001 0.3 (−2.5 to 3.1), .83 
 GMFCS I–II 39.9 (8.2) 50.4 (5.5) 10.6 (9.5), <.001 40.8 (5.6) 49.9 (3.9) 9.1 (4.5), <.001 0.7 (−2.6 to 4.0), .67 
 GMFCS III–IV 39.1 (6.1) 45.5 (6.1) 6.4 (6.6), .01 36.2 (6.7) 43.5 (7.1) 7.3 (8.2), .001 0.9 (−4.1 to 5.9), .72 
 GMFCS V 32.4 (4.4) 34.6 (4.5) 2.1 (4.3), .07 32.3 (5.3) 35.3 (2.7) 3.0 (5.1), .03 −0.8 (−3.3 to 1.7), .52 
DASS overalla        
 Overall 27.0 (22.4) 15.2 (15.3) 11.8 (20.9), <.001 29.2 (23.5) 17.0 (17.7) 12.3 (24.3), .002 −1.2 (−5.1 to 7.4), .71 
 GMFCS I–II 19.6 (15.2) 2.9 (6.7) 16.7 (17.7), .001 29.9 (29.1) 8.0 (9.4) 21.9 (27.1), .004 −4.4 (−10.1 to 1.4), .13 
 GMFCS III–IV 26.4 (25.9) 16.0 (15.1) 10.4 (15.1), .09 20.0 (17.3) 11.1 (12.7) 8.8 (19.4), .14 3.4 (−7.1 to 13.8), .51 
 GMFCS V 36.1 (23.6) 28.3 (11.1) 7.9 (22.0), .17 35.5 (19.7) 30.9 (19.9) 4.6 (22.3), .42 −2.8 (−13.9 to 8.3), .61 
DASS depression        
 Overall 8.9 (9.7) 5.5 (6.3) 3.4 (10.0), .02 9.7 (9.2) 6.0 (6.3) 3.7 (10.0), .02 −0.4 (−2.9 to 2.2), .78 
 GMFCS I–II 6.3 (8.6) 1.0 (2.2) 5.3 (9.2), .03 10.1 (10.7) 2.4 (3.6) 7.8 (11.4), .01 −1.5 (−3.5 to 0.6), .17 
 GMFCS III–IV 9.8 (11.4) 5.5 (6.4) 4.3 (11.2), .15 5.2 (5.9) 4.2 (4.6) 1.0 (6.1), .58 0.4 (−4.0 to 4.9), .84 
 GMFCS V 11.0 (8.9) 10.5 (5.8) 0.5 (9.5), .84 12.6 (8.5) 11.1 (6.5) 1.5 (10.0), .56 −0.4 (−4.9 to 4.0), .85 
DASS anxiety        
 Overall 6.8 (7.9) 2.8 (3.5) 3.9 (7.8), .001 7.8 (8.0) 3.7 (5.2) 4.1 (8.3), .002 −0.7 (−2.5 to 1.0), .40 
 GMFCS I–II 3.2 (2.7) 0.4 (1.5) 2.8 (3.9), .01 8.2 (10.1) 2.0 (2.6) 6.2 (9.6), .02 −1.2 (−2.6 to 0.3), .11 
 GMFCS III–IV 5.0 (6.9) 3.5 (3.5) 1.5 (7.0), .41 5.3 (7.1) 2.0 (3.2) 3.3 (6.4), .10 1.6 (−1.1 to 4.2), .23 
 GMFCS V 12.5 (9.4) 4.9 (3.7) 7.6 (10.4), .01 9.3 (6.0) 6.9 (6.9) 2.4 (8.1), .26 −2.1 (−6.3 to 2.0), .30 
DASS stress        
 Overall 11.4 (8.4) 6.7 (6.9) 4.5 (8.9), <.001 11.7 (8.2) 7.3 (8.0) 4.4 (8.5), .003 −0.3 (−3.2 to 2.6), .84 
 GMFCS I–II 10.0 (6.8) 1.4 (3.3) 8.6 (7.8), <.001 11.5 (9.1) 3.7 (4.9) 7.9 (7.2), <.001 −1.9 (−4.6 to 0.8), .16 
 GMFCS III–IV 11.6 (9.6) 7.0 (6.6) 4.6 (8.5), .05 9.5 (6.4) 5.0 (6.0) 4.5 (9.1), .12 1.5 (−3.4 to 6.4), .53 
 GMFCS V 12.6 (9.1) 12.9 (5.3) −0.3 (8.4), .91 13.6 (8.5) 12.9 (9.1) 0.7 (10.9), .79 0.2 (−5.0 to 5.5), .92 
PDMS-2 Total Motor Quotient        
 Overall 72.9 (23.4) 63.6 (24.4) −9.24 (14.4), <.001 65.9 (21.2) 59.4 (21.1) −6.9 (13.7), <.01 −1.2 (−6.8 to 4.5), .68 
 GMFCS I–II 94.1 (16.2) 87.4 (19.3) −6.7 (11.3), .02 79.5 (20.3) 74.2 (19.1) −5.2 (11.5), .08 0.7 (−7.7 to 9.1), .87 
 GMFCS III–IV 68.7 (18.2) 57.4 (18.5) −11.3 (18.5), .03 68.4 (17.8) 58.8 (23.3) −9.6 (18.6), .10 −1.6 (−15.4 to 12.3), .82 
 GMFCS V 53.1 (13.3) 43.0 (0.0) −10.1 (13.4), .01 49.6 (12.1) 43.0 (0.0) −6.6 (12.1), .05) NC 
PDMS-2 total raw score        
 Overall 61.4 (48.9) 129.1 (98.3) 67.7 (70.6), <.001 46.2 (40.8) 111.3 (96.3) 65.1 (69.2), <.001 −6.7 (−33.4 to 19.9), .62 
 GMFCS I–II 106.3 (36.4) 227.9 (50.0) 121.6 (57.3), <.001 72.4 (36.9) 194.5 (58.8) 122.1 (57.0), <.001 20.3 (−20.5 to 61.0), .32 
 GMFCS III–IV 53.5 (40.7) 120.7 (73.9) 67.2 (71.8), .01 55.1 (41.2) 114.8 (95.2) 59.8 (67.8), .01 7.6 (−48.5 to 63.8), .78 
 GMFCS V 18.8 (15.4) 26.3 (14.6) 7.6 (8.2), .01 11.8 (8.3) 20.2 (11.3) 8.4 (9.2), .01 0.5 (−6.0 to 6.9), .89 
PDMS-2 gross motor raw        
 Overall 35.8 (27.5) 67.1 (52.0) 31.3 (37.2), <.001 26.0 (21.8) 56.8 (49.8) 30.9 (34.3), <.001 −5.0 (−18.9 to 8.7), .47 
 GMFCS I–II 61.2 (19.1) 117.8 (33.6) 56.6 (36.2), <.001 40.4 (19.0) 99.7 (31.0) 59.2 (27.9), <.001 7.9 (−16.9 to 32.8), .52 
 GMFCS III–IV 31.7 (23.3) 61.9 (38.4) 30.2 (37.6), .01 30.8 (21.2) 56.9 (50.5) 26.1 (34.8), .03 4.0 (−25.2 to 33.2), .78 
 GMFCS V 11.4 (9.7) 15.3 (10.5) 3.9 (6.3), .03 7.0 (6.1) 11.3 (8.8) 4.3 (6.2), .01 −0.1 (−4.8 to 4.6), .97 
PDMS-2 fine motor raw        
 Overall 26.6 (22.4) 62.0 (48.0) 36.4 (36.2), <.001 20.2 (22.6) 54.4 (49.4) 34.2 (37.1), <.001 −0.5 (−14. 9 to 13.8), .94 
 GMFCS I–II 45.1 (18.6) 110.1 (20.1) 65.0 (25.7), <.001 32.0 (23.4) 94.9 (35.8) 62.9 (33.5), <.001 9.5 (−10.6 to 29.5), .34 
 GMFCS III–IV 21.8 (19.3) 58.8 (38.3) 37.0 (37.1), .001 24.3 (25.2) 57.9 (47.7) 33.7 (35.2), .01 3.4 (−25.8 to 32.5), .81 
 GMFCS V 7.4 (6.9) 11.1 (6.9) 3.7 (4.5), .01 4.8 (3.7) 8.9 (6.4) 4.1 (5.7), .01 0.1 (−3.7 to 3.9), .95 
BSID-III cognition standard score        
 Overall 69.5 (22.6) 69.3 (20.6) −0.2 (18.1), .94 69.3 (24.8) 67.0 (17.3) −2.3 (18.1), .40 2.2 (−3.7 to 8.0), .47 
 GMFCS I–II 84.2 (27.6) 87.5 (22.2) 3.3 (25.7), .59 86.2 (31.0) 77.5 (16.5) −8.7 (26.0), .19 10.7 (−1.2 to 22.6), .08 
 GMFCS III–IV 67.5 (18.1) 63.1 (13.2) −4.4 (17.0), .32 64.6 (17.6) 68.3 (20.4) 3.4 (14.6), .39 −6.7 (−17.7 to 4.2), .22 
 GMFCS V 55.0 (0.0) 55.0 (0.0) NC 55.0 (0.0) 55.0 (0.0) NC NC 
BSID-III cognition raw score        
 Overall 13.9 (12.2) 28.1 (19.7) 14.2 (13.9), <.001 12.8 (12.4) 24.4 (21.5) 11. 6 (13.9), <.001 2.3 (−3.3 to 7.8), .42 
 GMFCS I–II 22.7 (9.4) 46.6 (8.8) 23.9 (11.1), <.001 21.0 (11.6) 41.2 (15.0) 20.2 (14.6), <.001 4.7 (−3.3 to 12.7), .24 
 GMFCS III–IV 14.2 (12.7) 29.1 (15.2) 14.9 (14.7), .001 14.9 (12.1) 28.4 (20.7) 13.5 (13.2), .01 1.3 (−10.0 to 12.5), .82 
 GMFCS V 3.9 (5.2) 6.4 (6.1) 2.5 (3.8), .02 2.4 (1.4) 3.5 (2.3) 1.1 (1.9), .04 1.5 (−0.7 to 3.8), .17 
BSID-III language standard score        
 Overall 64.9 (20.4) 59.3 (15.4) −5.6 (14.5), <.01 62.0 (16.7) 56.4 (11.2) −5.6 (12.9), .01 1.5 (−2.6 to 5.6), .48 
 GMFCS I–II 81.4 (21.4) 71.4 (21.4) −10.0 (15.6), .02 75.9 (16.2) 65.1 (9.0) −10.8 (15.8), .01 4.4 (−2.7 to 11.4), .21 
 GMFCS III–IV 60.6 (15.2) 57.8 (14.2) −2.8 (18.1), .55 59.3 (11.3) 55.6 (12.2) −3.7 (11.9), .31 1.8 (−8.4 to 12.0), .72 
 GMFCS V 47.0 (0.0) 50.6 (6.5) −3.6 (6.5), .05 49.4 (7.0) 47.8 (3.3) −1.6 (7.9), .43 −0.8 (−2.5 to 0.9), .35 
BSID-III RL raw score        
 Overall 5.6 (3.4) 9.3 (5.4) 3.7 (3.8), <.001 4.9 (3.2) 9.0 (5.8) 4.1 (4.4), <.001 −0.5 (−2.2 to 1.1), .52 
 GMFCS I–II 8.0 (2.4) 14.2 (3.5) 6.2 (3.7), <.001 7.1 (2.9) 13.3 (3.7) 6.2 (4.0), <.001 0.6 (−1.9 to 3.1), .62 
 GMFCS III–IV 5.4 (3.4) 8.9 (4.1) 3.5 (3.6), .01 4.5 (3.0) 9.5 (6.4) 5.0 (5.5), .01 −1.3 (−5.0 to 2.3), .45 
 GMFCS V 3.1 (2.2) 4.1 (2.1) 1.0 (1.5), .02 2.8 (1.9) 2.2 (1.8) 1.3 (1.8), .02 −0.2 (−1.3 to 1.0), .78 
BSID-III EL raw score        
 Overall 4.1 (3.0) 7.0 (5.2) 2.9 (3.6), <.001 3.7 (2.7) 6.0 (4.9) 2.3 (3.0), <.001 0.4 (−0.9 to 1.6), .57 
 GMFCS I–II 6.7 (1.8) 11.3 (3.5) 4.6 (2.9), <.001 5.7 (2.1) 9.8 (3.8) 4.1 (3.2), <.001 0.5 (−1.7 to 2.7), .67 
 GMFCS III–IV 3.3 (2.4) 6.6 (4.8) 3.3 (4.7), .02 4.0 (2.2) 6.4 (4.6) 2.4 (2.8), .01 1.0 (−2.3 to 4.3), .54 
 GMFCS V 2.1 (2.4) 2.5 (2.5) 0.4 (0.9), .07 1.4 (1.6) 1.7 (1.8) 0.3 (0.8), .14 0.1 (−0.5 to 0.8), .68 
HINE score        
 Overall (n = 51) 42.3 (16.9) 56.4 (22.7) 14.2 (14.5), <.001 37.7 (13.8) 46.2 (20.4) 8.6 (17.6), .02 5.9 (−3.4 to 15.1), .21 
 GMFCS I–II (n = 16) 55.3 (13.0) 74.8 (3.2) 19.5 (11.2), <.001 46.9 (14.5) 67.6 (7.3) 20.8 (12.8), .01 5.5 (0.0 to 11.1), .05 
 GMFCS III–IV (n = 17) 41.3 (14.6) 57.6 (21.0) 16.3 (14.4), .01 42.9 (10.7) 48.3 (22.7) 5.4 (23.6), .57 10.7 (−9.6 to 31.0), .28 
 GMFCS V (n = 18) 26.9 (10.5) 31.1 (14.9) 4.3 (15.3), .49 28.5 (9.5) 31.3 (9.5) 2.9 (12.9), .48 0.2 (−12.2 to 12.6), .97 
COPM performance        
 Overall 2.3 (1.1) 6.3 (2.5) 4.0 (2.1), <.001 2.4 (0.9) 6.5 (2.7) 4.1 (2.3), <.001 0.0 (−0.9 to 0.9), .99 
 GMFCS I–II 2.7 (1.0) 8.2 (1.5) 5.5 (1.6), <.001 2.7 (0.9) 9.0 (1.4) 6.3 (1.6), <.001 −0.8 (−1.8 to 0.2), .12 
 GMFCS III–IV 2.4 (1.4) 6.5 (2.2) 4.1 (2.1), <.001 2.5 (0.9) 6.1 (2.1) 3.6 (1.5), <.001 0.5 (−0.9 to 2.0), .46 
 GMFCS V 1.6 (0.6) 3.7 (1.2) 2.1 (1.0), <.001 2.0 (0.9) 4.1 (1.7) 2.1 (1.2), <.001 0.2 (−0.7 to 1.1), .65 
COPM satisfaction        
 Overall 2.5 (1.5) 6.5 (2.6) 4.0 (2.3), <.001 2.6 (1.3) 6.6 (2.7) 4.0 (2.5), 0.001 0.0 (−1.0 to 1.0), .94 
 GMFCS I–II 3.1 (1.3) 8.4 (1.6) 5.3 (1.9), <.001 3.0 (1.6) 9.1 (1.4) 6.1 (2.0), <.001 −0.7 (−1.8 to 0.4), .21 
 GMFCS III–IV 2.5 (1.7) 6.9 (2.4) 4.4 (2.2), <.001 2.4 (1.0) 6.4 (2.2) 4.0 (1.7), <.001 0.4 (−1.1 to 2.0), .59 
 GMFCS V 1.9 (1.4) 4.0 (1.5) 2.1 (1.5), <.001 2.4 (1.3) 4.3 (1.8) 1.9 (1.3), <.001 0.1 (−1.0 to 1.1), .92 
Vision        
 Overall 4.9 (1.9) 5.7 (2.0) 0.8 (1.4), <.001 4.5 (2.0) 5.4 (2.0) 0.9 (1.2), <.001 0.0 (−0.5 to 0.5), .96 
 GMFCS I–II 5.8 (1.0) 7.0 (0.0) 1.2 (1.0), <.001 5.5 (1.9) 6.4 (1.8) 0.8 (1.1), .01 0.5 (−0.2 to 1.1), .13 
 GMFCS III–IV 5.3 (2.0) 5.9 (2.0) 0.6 (1.3), .07 4.8 (1.9) 6.0 (1.4) 1.2 (1.2), .01 −0.4 (−1.3 to 0.5), .34 
 GMFCS V 3.6 (1.9) 4.1 (1.8) 0.5 (1.9), .30 3.1 (1.4) 3.7 (1.5) 0.7 (1.5), .10 0.1 (−1.0 to 1.2), .87 
HOME        
 Overall 25.6 (5.3) 27.1 (4.9) 1.5 (5.0), .04 25.6 (4.7) 27.2 (4.1) 1.6 (3.5), .003 −0.1 (−1.6 to 1.4), .88 
 GMFCS I–II 27.8 (3.5) 28.5 (3.8) 0.7 (3.8), .40 26.1 (5.5) 28.2 (4.4) 2.1 (4.2), .05 −0.6 (−2.9 to 1.7), .60 
 GMFCS III–IV 25.6 (6.5) 26.6 (5.7) 0.9 (6.3), .56 26.1 (3.9) 27.5 (2.8) 1.4 (2.7), .10 −0.7 (−4.0 to 2.5), .64 
 GMFCS V 23.2 (5.0) 26.1 (5.0) 2.9 (4.9), .03 24.6 (4.4) 25.9 (4.4) 1.3 (3.5), .15 1.0 (−1.8 to 3.9), .46 
Length z-scores        
 Overall −1.9 (1.9) −2.3 (1.8) −0.4 (2.1), .19 −1.6 (2.0) −1.5 (1.7) 0.1 (2.4), .80 −0.7 (1.4 to 0.0), .05 
 GMFCS I–II −1.5 (1.7) −1.7 (1.3) 0.2 (1.7), .70 −0.8 (1.9) −0.8 (1.5) 0.0 (2.0), .87 −0.8 (−1.6 to 0.1), .07 
 GMFCS III–IV −2.5 (2.1) −2.3 (1.9) 0.2 (2.4), .79 −1.3 (1.7) −1.9 (1.7) −0.6 (2.1), .30 −0.1 (−1.6 to 1.4), .89 
 GMFCS V −1.7 (2.1) −2.9 (2.1) −1.2 (2.1), .03 −2.7 (1.9) −2.1 (1.9) 0.7 (2.8), .37 −1.1 (−2.6 to 0.4), .15 
Wt z-score        
 Overall −2.4 (1.7) −1.9 (1.9) 0.5 (1.7), .04 −1.9 (1.7) −1.7 (1.4) 0.2 (1.4), .44 0.1 (−0.4 to 0.7), .61 
 GMFCS I–II −1.5 (1.2) −0.8 (1.1) 0.7 (1.3), .04 −1.5 (1.4) −1.2 (1.2) 0.4 (1.1), .17 0.3 (−0.4 to 1.0), .35 
 GMFCS III–IV −3.0 (2.1) −2.2 (2.1) 0.8 (2.3), .22 −1.3 (1.1) −1.8 (1.3) 0.4 (1.2), .27 0.2 (−1.2 to 1.7), .75 
 GMFCS V −2.7 (1.2) −2.6 (1.9) 0.1 (1.3), .80 −2.7 (2.1) −2.3 (1.6) 0.4 (1.7), .41 −0.3 (−1.3 to 0.7), .57 
BMI z-scores        
 Overall −1.7 (1.7) −1.0 (2.0) 0.7 (1.4), .001 −1.3 (1.8) −0.9 (2.0) 0.4 (1.7), .17 0.3 (−0.3 to 0.9), .37 
 GMFCS I–II −0.8 (1.4) −0.1 (1.4) 0.8 (1.4), .04 −1.5 (-1.2) −1.2 (1.8) 0.2 (1.1), .40 0.7 (−0.1 to 1.6), .08 
 GMFCS III–IV −2.0 (2.0) −1.5 (2.3) 0.5 (1.3), .16 −0.8 (1.3) 0.1 (2.1) 0.9 (1.4), .06 −0.4 (−1.5 to 0.8), .53 
 GMFCS V −2.4 (1.4) −1.5 (2.1) 0.9 (1.6), .04 −1.4 (2.2) −1.3 (2.1) −0.1 (2.2), .88 0.4 (−0.9 to 1.8), .52 
PSOC        
 Overall 63.5 (8.7) 70.1 (10.7) 6.6 (9.3), <.001 63.8 (9.6) 69.7 (10.4) 5.8 (10.7), .001 0.7 (−3.1 to 4.4), .73 
 GMFCS I–II 68.2 (8.2) 74.7 (11.2) 6.4 (10.9), .02 66.5 (9.3) 75.8 (9.3) 9.2 (9.1), .001 −2.0 (−8.5 to 4.4), .53 
 GMFCS III–IV 62.6 (7.0) 70.4 (8.6) 7.9 (8.1), .001 64.5 (7.2) 67.6 (9.5) 3.1 (10.6), .34 3.7 (−3.1 to 10.5), .27 
 GMFCS V 59.3 (8.6) 64.8 (10.2) 5.5 (8.9), .03 60.5 (10.8) 64.8 (9.4) 4.3 (12.1), .18 0.5 (−6.1 to 7.1), .87 
LEAP-CP, n = 50Health Advice n = 46Adjusted Between-group
Baseline Mean Score (SD)Final Mean Score (SD)Pre to Post Mean Difference (SD), PBaseline Mean Score (SD)Final Mean Score (SD)Pre to Post Mean Difference (SD), PFinal Outcome Adj Mean Difference (95% CI), P
PEDI-CAT mobility (SS)a        
 Overall 42.7 (5.1) 48.4 (8.2) 5.7 (6.5), <.001 33.5 (3.9) 38.0 (5.2) 4.5 (5.5), <.001 1.9 (−0.8 to 4.6), .16 
 GMFCS I–II 46.4 (4.1) 56.3 (3.8) 9.9 (5.5), <.001 45.4 (3.2) 52.4 (3.3) 7.0 (4.5), <.001 4.0 (1.4 to 6.5), .003 
 GMFCS III–IV 41.9 (5.6) 48.3 (5.6) 6.4 (6.2), <.001 43.8 (3.2) 48.3 (8.6) 4.5 (7.5), .06 1.1 (−4.2 to 6.5), .67 
 GMFCS V 39.2 (3.3) 39.6 (3.6) 0.4 (3.7), .69 38.1 (5.2) 38.1 (3.4) 0.1 (6.3), .97 1.4 (−1.2 to 4.0), .29 
PEDI-CAT DA (SS)        
 Overall 33.8 (4.4) 38.7 (5.0) 4.9 (5.1), <.001 33.5 (3.9) 38.0 (5.2) 4.5 (5.5), <.001 0.6 (−1.3 to 2.6), .52 
 GMFCS I–II 35.7 (5.4) 42.4 (4.4) 6.7 (6.6), <.001 34.5 (4.1) 42.1 (3.9) 7.6 (5.0), <.001 0.1 (−2.8 to 3.0), .93 
 GMFCS III–IV 33.9 (3.9) 39.4 (3.9) 5.6 (3.6), <.001 34.2 (4.7) 38.5 (4.8) 4.3 (6.7), .05 1.0 (−2.3 to 4.3), .55 
 GMFCS V 31.5 (2.1) 33.9 (1.8) 2.4 (2.4), .001 31.8 (2.6) 33.1 (1.3) 1.3 (2.7), .06 0.8 (−0.3 to 1.9), .15 
PEDI-CAT SC (SS)        
 Overall 37.3 (7.2) 43.8 (8.6) 6.5 (7.9), <.001 36.5 (6.8) 43.0 (7.8) 6.5 (6.3), <.001 0.3 (−2.5 to 3.1), .83 
 GMFCS I–II 39.9 (8.2) 50.4 (5.5) 10.6 (9.5), <.001 40.8 (5.6) 49.9 (3.9) 9.1 (4.5), <.001 0.7 (−2.6 to 4.0), .67 
 GMFCS III–IV 39.1 (6.1) 45.5 (6.1) 6.4 (6.6), .01 36.2 (6.7) 43.5 (7.1) 7.3 (8.2), .001 0.9 (−4.1 to 5.9), .72 
 GMFCS V 32.4 (4.4) 34.6 (4.5) 2.1 (4.3), .07 32.3 (5.3) 35.3 (2.7) 3.0 (5.1), .03 −0.8 (−3.3 to 1.7), .52 
DASS overalla        
 Overall 27.0 (22.4) 15.2 (15.3) 11.8 (20.9), <.001 29.2 (23.5) 17.0 (17.7) 12.3 (24.3), .002 −1.2 (−5.1 to 7.4), .71 
 GMFCS I–II 19.6 (15.2) 2.9 (6.7) 16.7 (17.7), .001 29.9 (29.1) 8.0 (9.4) 21.9 (27.1), .004 −4.4 (−10.1 to 1.4), .13 
 GMFCS III–IV 26.4 (25.9) 16.0 (15.1) 10.4 (15.1), .09 20.0 (17.3) 11.1 (12.7) 8.8 (19.4), .14 3.4 (−7.1 to 13.8), .51 
 GMFCS V 36.1 (23.6) 28.3 (11.1) 7.9 (22.0), .17 35.5 (19.7) 30.9 (19.9) 4.6 (22.3), .42 −2.8 (−13.9 to 8.3), .61 
DASS depression        
 Overall 8.9 (9.7) 5.5 (6.3) 3.4 (10.0), .02 9.7 (9.2) 6.0 (6.3) 3.7 (10.0), .02 −0.4 (−2.9 to 2.2), .78 
 GMFCS I–II 6.3 (8.6) 1.0 (2.2) 5.3 (9.2), .03 10.1 (10.7) 2.4 (3.6) 7.8 (11.4), .01 −1.5 (−3.5 to 0.6), .17 
 GMFCS III–IV 9.8 (11.4) 5.5 (6.4) 4.3 (11.2), .15 5.2 (5.9) 4.2 (4.6) 1.0 (6.1), .58 0.4 (−4.0 to 4.9), .84 
 GMFCS V 11.0 (8.9) 10.5 (5.8) 0.5 (9.5), .84 12.6 (8.5) 11.1 (6.5) 1.5 (10.0), .56 −0.4 (−4.9 to 4.0), .85 
DASS anxiety        
 Overall 6.8 (7.9) 2.8 (3.5) 3.9 (7.8), .001 7.8 (8.0) 3.7 (5.2) 4.1 (8.3), .002 −0.7 (−2.5 to 1.0), .40 
 GMFCS I–II 3.2 (2.7) 0.4 (1.5) 2.8 (3.9), .01 8.2 (10.1) 2.0 (2.6) 6.2 (9.6), .02 −1.2 (−2.6 to 0.3), .11 
 GMFCS III–IV 5.0 (6.9) 3.5 (3.5) 1.5 (7.0), .41 5.3 (7.1) 2.0 (3.2) 3.3 (6.4), .10 1.6 (−1.1 to 4.2), .23 
 GMFCS V 12.5 (9.4) 4.9 (3.7) 7.6 (10.4), .01 9.3 (6.0) 6.9 (6.9) 2.4 (8.1), .26 −2.1 (−6.3 to 2.0), .30 
DASS stress        
 Overall 11.4 (8.4) 6.7 (6.9) 4.5 (8.9), <.001 11.7 (8.2) 7.3 (8.0) 4.4 (8.5), .003 −0.3 (−3.2 to 2.6), .84 
 GMFCS I–II 10.0 (6.8) 1.4 (3.3) 8.6 (7.8), <.001 11.5 (9.1) 3.7 (4.9) 7.9 (7.2), <.001 −1.9 (−4.6 to 0.8), .16 
 GMFCS III–IV 11.6 (9.6) 7.0 (6.6) 4.6 (8.5), .05 9.5 (6.4) 5.0 (6.0) 4.5 (9.1), .12 1.5 (−3.4 to 6.4), .53 
 GMFCS V 12.6 (9.1) 12.9 (5.3) −0.3 (8.4), .91 13.6 (8.5) 12.9 (9.1) 0.7 (10.9), .79 0.2 (−5.0 to 5.5), .92 
PDMS-2 Total Motor Quotient        
 Overall 72.9 (23.4) 63.6 (24.4) −9.24 (14.4), <.001 65.9 (21.2) 59.4 (21.1) −6.9 (13.7), <.01 −1.2 (−6.8 to 4.5), .68 
 GMFCS I–II 94.1 (16.2) 87.4 (19.3) −6.7 (11.3), .02 79.5 (20.3) 74.2 (19.1) −5.2 (11.5), .08 0.7 (−7.7 to 9.1), .87 
 GMFCS III–IV 68.7 (18.2) 57.4 (18.5) −11.3 (18.5), .03 68.4 (17.8) 58.8 (23.3) −9.6 (18.6), .10 −1.6 (−15.4 to 12.3), .82 
 GMFCS V 53.1 (13.3) 43.0 (0.0) −10.1 (13.4), .01 49.6 (12.1) 43.0 (0.0) −6.6 (12.1), .05) NC 
PDMS-2 total raw score        
 Overall 61.4 (48.9) 129.1 (98.3) 67.7 (70.6), <.001 46.2 (40.8) 111.3 (96.3) 65.1 (69.2), <.001 −6.7 (−33.4 to 19.9), .62 
 GMFCS I–II 106.3 (36.4) 227.9 (50.0) 121.6 (57.3), <.001 72.4 (36.9) 194.5 (58.8) 122.1 (57.0), <.001 20.3 (−20.5 to 61.0), .32 
 GMFCS III–IV 53.5 (40.7) 120.7 (73.9) 67.2 (71.8), .01 55.1 (41.2) 114.8 (95.2) 59.8 (67.8), .01 7.6 (−48.5 to 63.8), .78 
 GMFCS V 18.8 (15.4) 26.3 (14.6) 7.6 (8.2), .01 11.8 (8.3) 20.2 (11.3) 8.4 (9.2), .01 0.5 (−6.0 to 6.9), .89 
PDMS-2 gross motor raw        
 Overall 35.8 (27.5) 67.1 (52.0) 31.3 (37.2), <.001 26.0 (21.8) 56.8 (49.8) 30.9 (34.3), <.001 −5.0 (−18.9 to 8.7), .47 
 GMFCS I–II 61.2 (19.1) 117.8 (33.6) 56.6 (36.2), <.001 40.4 (19.0) 99.7 (31.0) 59.2 (27.9), <.001 7.9 (−16.9 to 32.8), .52 
 GMFCS III–IV 31.7 (23.3) 61.9 (38.4) 30.2 (37.6), .01 30.8 (21.2) 56.9 (50.5) 26.1 (34.8), .03 4.0 (−25.2 to 33.2), .78 
 GMFCS V 11.4 (9.7) 15.3 (10.5) 3.9 (6.3), .03 7.0 (6.1) 11.3 (8.8) 4.3 (6.2), .01 −0.1 (−4.8 to 4.6), .97 
PDMS-2 fine motor raw        
 Overall 26.6 (22.4) 62.0 (48.0) 36.4 (36.2), <.001 20.2 (22.6) 54.4 (49.4) 34.2 (37.1), <.001 −0.5 (−14. 9 to 13.8), .94 
 GMFCS I–II 45.1 (18.6) 110.1 (20.1) 65.0 (25.7), <.001 32.0 (23.4) 94.9 (35.8) 62.9 (33.5), <.001 9.5 (−10.6 to 29.5), .34 
 GMFCS III–IV 21.8 (19.3) 58.8 (38.3) 37.0 (37.1), .001 24.3 (25.2) 57.9 (47.7) 33.7 (35.2), .01 3.4 (−25.8 to 32.5), .81 
 GMFCS V 7.4 (6.9) 11.1 (6.9) 3.7 (4.5), .01 4.8 (3.7) 8.9 (6.4) 4.1 (5.7), .01 0.1 (−3.7 to 3.9), .95 
BSID-III cognition standard score        
 Overall 69.5 (22.6) 69.3 (20.6) −0.2 (18.1), .94 69.3 (24.8) 67.0 (17.3) −2.3 (18.1), .40 2.2 (−3.7 to 8.0), .47 
 GMFCS I–II 84.2 (27.6) 87.5 (22.2) 3.3 (25.7), .59 86.2 (31.0) 77.5 (16.5) −8.7 (26.0), .19 10.7 (−1.2 to 22.6), .08 
 GMFCS III–IV 67.5 (18.1) 63.1 (13.2) −4.4 (17.0), .32 64.6 (17.6) 68.3 (20.4) 3.4 (14.6), .39 −6.7 (−17.7 to 4.2), .22 
 GMFCS V 55.0 (0.0) 55.0 (0.0) NC 55.0 (0.0) 55.0 (0.0) NC NC 
BSID-III cognition raw score        
 Overall 13.9 (12.2) 28.1 (19.7) 14.2 (13.9), <.001 12.8 (12.4) 24.4 (21.5) 11. 6 (13.9), <.001 2.3 (−3.3 to 7.8), .42 
 GMFCS I–II 22.7 (9.4) 46.6 (8.8) 23.9 (11.1), <.001 21.0 (11.6) 41.2 (15.0) 20.2 (14.6), <.001 4.7 (−3.3 to 12.7), .24 
 GMFCS III–IV 14.2 (12.7) 29.1 (15.2) 14.9 (14.7), .001 14.9 (12.1) 28.4 (20.7) 13.5 (13.2), .01 1.3 (−10.0 to 12.5), .82 
 GMFCS V 3.9 (5.2) 6.4 (6.1) 2.5 (3.8), .02 2.4 (1.4) 3.5 (2.3) 1.1 (1.9), .04 1.5 (−0.7 to 3.8), .17 
BSID-III language standard score        
 Overall 64.9 (20.4) 59.3 (15.4) −5.6 (14.5), <.01 62.0 (16.7) 56.4 (11.2) −5.6 (12.9), .01 1.5 (−2.6 to 5.6), .48 
 GMFCS I–II 81.4 (21.4) 71.4 (21.4) −10.0 (15.6), .02 75.9 (16.2) 65.1 (9.0) −10.8 (15.8), .01 4.4 (−2.7 to 11.4), .21 
 GMFCS III–IV 60.6 (15.2) 57.8 (14.2) −2.8 (18.1), .55 59.3 (11.3) 55.6 (12.2) −3.7 (11.9), .31 1.8 (−8.4 to 12.0), .72 
 GMFCS V 47.0 (0.0) 50.6 (6.5) −3.6 (6.5), .05 49.4 (7.0) 47.8 (3.3) −1.6 (7.9), .43 −0.8 (−2.5 to 0.9), .35 
BSID-III RL raw score        
 Overall 5.6 (3.4) 9.3 (5.4) 3.7 (3.8), <.001 4.9 (3.2) 9.0 (5.8) 4.1 (4.4), <.001 −0.5 (−2.2 to 1.1), .52 
 GMFCS I–II 8.0 (2.4) 14.2 (3.5) 6.2 (3.7), <.001 7.1 (2.9) 13.3 (3.7) 6.2 (4.0), <.001 0.6 (−1.9 to 3.1), .62 
 GMFCS III–IV 5.4 (3.4) 8.9 (4.1) 3.5 (3.6), .01 4.5 (3.0) 9.5 (6.4) 5.0 (5.5), .01 −1.3 (−5.0 to 2.3), .45 
 GMFCS V 3.1 (2.2) 4.1 (2.1) 1.0 (1.5), .02 2.8 (1.9) 2.2 (1.8) 1.3 (1.8), .02 −0.2 (−1.3 to 1.0), .78 
BSID-III EL raw score        
 Overall 4.1 (3.0) 7.0 (5.2) 2.9 (3.6), <.001 3.7 (2.7) 6.0 (4.9) 2.3 (3.0), <.001 0.4 (−0.9 to 1.6), .57 
 GMFCS I–II 6.7 (1.8) 11.3 (3.5) 4.6 (2.9), <.001 5.7 (2.1) 9.8 (3.8) 4.1 (3.2), <.001 0.5 (−1.7 to 2.7), .67 
 GMFCS III–IV 3.3 (2.4) 6.6 (4.8) 3.3 (4.7), .02 4.0 (2.2) 6.4 (4.6) 2.4 (2.8), .01 1.0 (−2.3 to 4.3), .54 
 GMFCS V 2.1 (2.4) 2.5 (2.5) 0.4 (0.9), .07 1.4 (1.6) 1.7 (1.8) 0.3 (0.8), .14 0.1 (−0.5 to 0.8), .68 
HINE score        
 Overall (n = 51) 42.3 (16.9) 56.4 (22.7) 14.2 (14.5), <.001 37.7 (13.8) 46.2 (20.4) 8.6 (17.6), .02 5.9 (−3.4 to 15.1), .21 
 GMFCS I–II (n = 16) 55.3 (13.0) 74.8 (3.2) 19.5 (11.2), <.001 46.9 (14.5) 67.6 (7.3) 20.8 (12.8), .01 5.5 (0.0 to 11.1), .05 
 GMFCS III–IV (n = 17) 41.3 (14.6) 57.6 (21.0) 16.3 (14.4), .01 42.9 (10.7) 48.3 (22.7) 5.4 (23.6), .57 10.7 (−9.6 to 31.0), .28 
 GMFCS V (n = 18) 26.9 (10.5) 31.1 (14.9) 4.3 (15.3), .49 28.5 (9.5) 31.3 (9.5) 2.9 (12.9), .48 0.2 (−12.2 to 12.6), .97 
COPM performance        
 Overall 2.3 (1.1) 6.3 (2.5) 4.0 (2.1), <.001 2.4 (0.9) 6.5 (2.7) 4.1 (2.3), <.001 0.0 (−0.9 to 0.9), .99 
 GMFCS I–II 2.7 (1.0) 8.2 (1.5) 5.5 (1.6), <.001 2.7 (0.9) 9.0 (1.4) 6.3 (1.6), <.001 −0.8 (−1.8 to 0.2), .12 
 GMFCS III–IV 2.4 (1.4) 6.5 (2.2) 4.1 (2.1), <.001 2.5 (0.9) 6.1 (2.1) 3.6 (1.5), <.001 0.5 (−0.9 to 2.0), .46 
 GMFCS V 1.6 (0.6) 3.7 (1.2) 2.1 (1.0), <.001 2.0 (0.9) 4.1 (1.7) 2.1 (1.2), <.001 0.2 (−0.7 to 1.1), .65 
COPM satisfaction        
 Overall 2.5 (1.5) 6.5 (2.6) 4.0 (2.3), <.001 2.6 (1.3) 6.6 (2.7) 4.0 (2.5), 0.001 0.0 (−1.0 to 1.0), .94 
 GMFCS I–II 3.1 (1.3) 8.4 (1.6) 5.3 (1.9), <.001 3.0 (1.6) 9.1 (1.4) 6.1 (2.0), <.001 −0.7 (−1.8 to 0.4), .21 
 GMFCS III–IV 2.5 (1.7) 6.9 (2.4) 4.4 (2.2), <.001 2.4 (1.0) 6.4 (2.2) 4.0 (1.7), <.001 0.4 (−1.1 to 2.0), .59 
 GMFCS V 1.9 (1.4) 4.0 (1.5) 2.1 (1.5), <.001 2.4 (1.3) 4.3 (1.8) 1.9 (1.3), <.001 0.1 (−1.0 to 1.1), .92 
Vision        
 Overall 4.9 (1.9) 5.7 (2.0) 0.8 (1.4), <.001 4.5 (2.0) 5.4 (2.0) 0.9 (1.2), <.001 0.0 (−0.5 to 0.5), .96 
 GMFCS I–II 5.8 (1.0) 7.0 (0.0) 1.2 (1.0), <.001 5.5 (1.9) 6.4 (1.8) 0.8 (1.1), .01 0.5 (−0.2 to 1.1), .13 
 GMFCS III–IV 5.3 (2.0) 5.9 (2.0) 0.6 (1.3), .07 4.8 (1.9) 6.0 (1.4) 1.2 (1.2), .01 −0.4 (−1.3 to 0.5), .34 
 GMFCS V 3.6 (1.9) 4.1 (1.8) 0.5 (1.9), .30 3.1 (1.4) 3.7 (1.5) 0.7 (1.5), .10 0.1 (−1.0 to 1.2), .87 
HOME        
 Overall 25.6 (5.3) 27.1 (4.9) 1.5 (5.0), .04 25.6 (4.7) 27.2 (4.1) 1.6 (3.5), .003 −0.1 (−1.6 to 1.4), .88 
 GMFCS I–II 27.8 (3.5) 28.5 (3.8) 0.7 (3.8), .40 26.1 (5.5) 28.2 (4.4) 2.1 (4.2), .05 −0.6 (−2.9 to 1.7), .60 
 GMFCS III–IV 25.6 (6.5) 26.6 (5.7) 0.9 (6.3), .56 26.1 (3.9) 27.5 (2.8) 1.4 (2.7), .10 −0.7 (−4.0 to 2.5), .64 
 GMFCS V 23.2 (5.0) 26.1 (5.0) 2.9 (4.9), .03 24.6 (4.4) 25.9 (4.4) 1.3 (3.5), .15 1.0 (−1.8 to 3.9), .46 
Length z-scores        
 Overall −1.9 (1.9) −2.3 (1.8) −0.4 (2.1), .19 −1.6 (2.0) −1.5 (1.7) 0.1 (2.4), .80 −0.7 (1.4 to 0.0), .05 
 GMFCS I–II −1.5 (1.7) −1.7 (1.3) 0.2 (1.7), .70 −0.8 (1.9) −0.8 (1.5) 0.0 (2.0), .87 −0.8 (−1.6 to 0.1), .07 
 GMFCS III–IV −2.5 (2.1) −2.3 (1.9) 0.2 (2.4), .79 −1.3 (1.7) −1.9 (1.7) −0.6 (2.1), .30 −0.1 (−1.6 to 1.4), .89 
 GMFCS V −1.7 (2.1) −2.9 (2.1) −1.2 (2.1), .03 −2.7 (1.9) −2.1 (1.9) 0.7 (2.8), .37 −1.1 (−2.6 to 0.4), .15 
Wt z-score        
 Overall −2.4 (1.7) −1.9 (1.9) 0.5 (1.7), .04 −1.9 (1.7) −1.7 (1.4) 0.2 (1.4), .44 0.1 (−0.4 to 0.7), .61 
 GMFCS I–II −1.5 (1.2) −0.8 (1.1) 0.7 (1.3), .04 −1.5 (1.4) −1.2 (1.2) 0.4 (1.1), .17 0.3 (−0.4 to 1.0), .35 
 GMFCS III–IV −3.0 (2.1) −2.2 (2.1) 0.8 (2.3), .22 −1.3 (1.1) −1.8 (1.3) 0.4 (1.2), .27 0.2 (−1.2 to 1.7), .75 
 GMFCS V −2.7 (1.2) −2.6 (1.9) 0.1 (1.3), .80 −2.7 (2.1) −2.3 (1.6) 0.4 (1.7), .41 −0.3 (−1.3 to 0.7), .57 
BMI z-scores        
 Overall −1.7 (1.7) −1.0 (2.0) 0.7 (1.4), .001 −1.3 (1.8) −0.9 (2.0) 0.4 (1.7), .17 0.3 (−0.3 to 0.9), .37 
 GMFCS I–II −0.8 (1.4) −0.1 (1.4) 0.8 (1.4), .04 −1.5 (-1.2) −1.2 (1.8) 0.2 (1.1), .40 0.7 (−0.1 to 1.6), .08 
 GMFCS III–IV −2.0 (2.0) −1.5 (2.3) 0.5 (1.3), .16 −0.8 (1.3) 0.1 (2.1) 0.9 (1.4), .06 −0.4 (−1.5 to 0.8), .53 
 GMFCS V −2.4 (1.4) −1.5 (2.1) 0.9 (1.6), .04 −1.4 (2.2) −1.3 (2.1) −0.1 (2.2), .88 0.4 (−0.9 to 1.8), .52 
PSOC        
 Overall 63.5 (8.7) 70.1 (10.7) 6.6 (9.3), <.001 63.8 (9.6) 69.7 (10.4) 5.8 (10.7), .001 0.7 (−3.1 to 4.4), .73 
 GMFCS I–II 68.2 (8.2) 74.7 (11.2) 6.4 (10.9), .02 66.5 (9.3) 75.8 (9.3) 9.2 (9.1), .001 −2.0 (−8.5 to 4.4), .53 
 GMFCS III–IV 62.6 (7.0) 70.4 (8.6) 7.9 (8.1), .001 64.5 (7.2) 67.6 (9.5) 3.1 (10.6), .34 3.7 (−3.1 to 10.5), .27 
 GMFCS V 59.3 (8.6) 64.8 (10.2) 5.5 (8.9), .03 60.5 (10.8) 64.8 (9.4) 4.3 (12.1), .18 0.5 (−6.1 to 7.1), .87 

COPM, Canadian Occupational Performance Measure; DA, Daily Activities domain; NC, Not Calculable; NVD, Near Vision Detection; SC, social-communication domain; SS, scaled score.

a

Primary infant and caregiver outcomes.

Within-group Change for Children With CP and Alike Conditions

There were significant improvements between enrollment and study completion for all outcomes overall for both study arms (Table 4). There were, however, no significant changes on (1) weight and BMI Z-scores (HA) and (2) length Z-scores (LEAP-CP, HA). There were significant declines on (1) PDMS total motor quotient (TMQ) (LEAP-CP, HA), and (2) BSID-III language composites (LEAP-CP, HA). Improvements were observed for all outcomes for children classified GMFCS I and II in both study arms; except for no significant change on (1) HOME (LEAP-CP), (2) length Z-score (LEAP-CP, HA), and (3) weight and BMI Z-scores (HA); and significant declines on (1) TMQ (LEAP-CP) and (2) BSID language composite (LEAP-CP, HA).

Association Between Participant Characteristics and Outcomes

Child factors were associated with a greater number of study outcomes compared with family or community factors (Supplemental Table 5 and 6). The family and community factors most frequently associated with better scores on outcomes were site (hospital referrals had poorer scores), lower poverty (PMT and SRI), and older caregiver age. Of broader influence, better child function (GMFCS, vision, undernutrition, and seizures) had significant positive associations with almost all outcomes. GMFCS was also associated with exposure variables of site, child’s age, vision, undernutrition, and seizures.

In this large pragmatic RCT of a peer-delivered multidomain early intervention for infants at risk for CP in a LMIC there were no significant overall improvements for infants or caregivers receiving LEAP-CP compared with dose-matched peer-delivered HA at 18 months CA. LEAP-CP did, however, improve parent-reported motor skills (PEDI-CAT) and neurologic status (HINE) in ambulatory children with CP (on secondary subgroup analysis). This is consistent with the literature from high-income countries, showing ambulatory children with CP have greater response to targeted motor training, with little to no response reported in nonambulatory children.46 48  There were also clinically and statistically significant improvements observed on almost all child and caregiver outcomes for both intervention arms during the course of the study, which suggests that the parent-delivered model in LMIC may be beneficial. In the absence of a true “control arm,” it is not possible, however, to determine the extent of improvements related to the interventions, as opposed to time and child-development. The age-standardized BSID-cognition composite evidenced no-significant change during the study period, which is a positive finding given standard scores for children with CP frequently decline relative to their same aged-peers.46  This pattern of age-referenced decline was noted on PDMS-TMQ and BSID language-composites, which suggests that although these outcomes improved in absolute terms, they did not track according to the child’s age.

The lack of between-group differences found in the primary analysis and overall mITT analysis may have been influenced by a number of factors, including the provision of an active dose-matched control program (including all infants accessing the community-based screening, which reduced the age of identification), greater severity of the sample (representative of CP in LMIC),5  and trends toward greater disadvantage in the LEAP-CP group (almost twice the rates of extreme poverty, higher rates of severe-profound undernutrition and poor vision). These factors are among those that have been reported to reduce responsiveness to intervention and between-group treatment effects in other early intervention studies for infants with CP.48,49 

Both study arms had clinically and statistically important improvements for almost all outcomes, indicating the benefits of parent support delivered by peer trainers in this context. LEAP-CP and HA were delivered by CDWs, who were women from the local community with a wealth of relevant lived experience (motherhood, having a child with a disability or complex health condition, having a physical disability themselves) and/or related work experience (special education, developmental therapy, maternal-child health, or nutrition). Although no active training component was provided to HA and efforts were made to minimize contamination, there were likely benefits arising from existing skills of the CDWs and the therapeutic alliance itself. The literature shows that peer supporters instill hope and facilitate service involvement50 ; and that building strong therapeutic alliances encourage engagement, satisfaction, and positive outcomes in allied health programs.51,52  Our findings suggest that the peer supported parent-delivered model used in both study arms may be effective in this LMIC context and that gains in the active control group may have obscured some of the between-group differences.

Differences in the CP etiology and brain lesions in LMICs6  result in a population skewed toward poorer motor function and greater rates of comorbidities.5  Only a third (38%) of children in the current study were independently ambulant (compared with >60% in high-income countries), consistent with the LMIC CP registers (15% to 45%).5  This skewed sample may result in (1) reduced ability of tools to detect change; (2) greater proportion of infants with lower response to the active training intervention (ie, GMFCS IV–V); and (3) reduced efficacy of the LEAP-CP content for the sample overall. Measuring change remains a significant challenge in heterogenous samples, as tools that are sensitive to measure change in GMFCS Vs, often have large variance in GMFCS I and IIs (as seen in the current study with the PDMS-2). This may have obscured between-group differences, particularly in the unstratified primary analysis. There was also limited assessment and medical management of comorbidities (seizures, cortical visual impairment and severe-profound undernutrition) for this study’s participants, which are known confounders to intervention responsiveness.53  Considering these context specific factors, the focus of the LEAP-CP intervention content, which was informed by the GAME trial27  and Learning Games curriculum (positive effects in children with diplegia)54  may need further development (including the addition of low-cost technology) to better support infants with complex clinical profiles common in LMICs. Additionally, future studies could consider limiting the recruitment to GMFCS I and II to reduce heterogeneity.

Length Z-scores were the only other outcome with significant between-group differences (mITT) that favored HA, but this finding may be a false positive (P = .05). This difference is driven by a marked decrease in length Z-score for the LEAP-CP GMFCS-V group. Although this decrease may represent a true deceleration in linear growth, it is likely caused by measurement error, which can be challenging in infants.55  Both LEAP-CP and HA received equivalent input regarding feeding and nutrition. A myriad of factors influence growth in this context, and nutrient intake may have been insufficiently modified to facilitate catch-up growth in a context where stunting is prevalent even in the general population (31%).56,57  Despite this, weight and BMI Z-scores of the LEAP-CP GMFCS-I and II group improved significantly from baseline to final, which was not observed for HA. Longer term follow-up is required to determine the effects of LEAP-CP on growth.

A significant difference was found in parenting competence (PSOC) during the course of the study for LEAP-CP (for all GMFCS levels), whereas a significant improvement was only detected for GMFCS-I and II for HA (mITT). This pattern was further reflected in changes to caregiver mental health postintervention. Caregiver mental health improved significantly for both arms overall and for GMFCS-I and II. There were additional improvements post-LEAP-CP for caregivers of infants GMFCS-III and IV for stress, and GMFCS-V for anxiety. This suggests that LEAP-CP may have further supported perceived competence of caregivers of children with nonambulatory CP above and beyond HA, which may have had associated benefits for caregiver stress and anxiety. LEAP-CP may have supported this through (1) emphasizing parental values, experiential acceptance, mindfulness, and responsive caregiving (informed by Acceptance Commitment Therapy)58,59 ; (2) peer-delivered support and capacity building of the caregiver as the primary change agent (education, coaching, collaborative problem-solving, picture-based home programs)60,61 ; and (3) prioritizing caregiver-identified meaningful goals. Improvements to parenting competence and mental health after relationally-focused early intervention is supported in the literature.62 

This large pragmatic RCT of a novel peer-delivered intervention tailored to the local context was conducted across 3 geographies and partner agencies from different sectors (government, nongovernment, private) in West Bengal India. It was delivered as a free home-based service to families from vulnerable circumstances with low health literacy and was embedded within the organizational and community contexts. These implementation choices brought richness to understanding the program in this real-world setting but also presented some limitations that may have reduced the between-group differences needed to demonstrate efficacy. Most notably, the active control arm (World Health Organization HA) poses challenges to disentangle the effects resulting from the LEAP-CP content versus the service delivery model or shared content for both study arms (fortnightly peer home visits, including feeding, nutrition, and health advice). In addition, given the context and service delivery model, it is plausible that families with very low program engagement participated, which may have reduced intervention effects compared with other studies in LMICs (particularly center-based programs). A measure of family’s engagement with the program and daily caregiver-dose were not measured, and this may have provided greater indication of the quality and quantity of enactment and its impact on outcomes.

Almost a fifth of the sample included in the primary analysis had typical development based on the eligibility screening in the community. The better outcomes of children with typical development may have obscured overall between-group differences for the CP sample. This limitation was addressed by conducting mITT analysis (excluding children with typical development); however, this also decreased the sample size. Power was further compounded by large variance in many outcomes and attrition >20%. Use of the GMFCS in infants at 18 months CA is also less accurate than use in later childhood and may have influenced the stratified analysis.63 

For pragmatic and ethical reasons, the study did not exclude children with significant comorbidities, including uncontrolled seizures, severe-profound undernutrition, significant cortical visual impairment; all of which are known to reduce intervention responsiveness. Finally, as this RCT was conducted in conjunction with the LEAP-CP program’s first implementation, the CDW’s fidelity may have been reduced while workers gained experience and confidence in delivering the program.

This large pragmatic RCT of the LEAP-CP multidomain early intervention compared with dose-matched HA in an LMIC found no significant between-group differences. Consistent with what is known about targeted training, children with ambulatory CP receiving LEAP-CP did, however, have better motor outcomes. LEAP-CP may have led to better outcomes in parenting competence and caregiver mental health in children GMFCS III through V. There were significant differences from baseline to postintervention on almost all outcomes (caregiver mental health, motor, cognition, language, goal performance, vision, home environment, nutritional status, parenting competence), which supports further investigation into the efficacy of the peer-delivered model for families with an infant with CP living in LMICs.

We thank the invaluable contributions of the implementing partner organizations for the LEAP-CP trial, specifically, the teams at the Child in Need Institute (Ms Monidipa Ghosh and Ms Shirin Parveen); Asha Bhavan Centre (Mr Johnmary Barui, Ms Mohua Manna); Dr BC Roy Postgraduate Institute of Pediatric Sciences (Mr Debasis Gantait). We would also like to acknowlede the contribution of Apollo Gleneagles Hospital as the host of the Endeavour Scholarship (Mr Jewel Chakraborty); and the Indian Institute of Cerebral Palsy as research partner (Dr Reena Sen). Finally, we acknowledge the support of the Queensland Cerebral Palsy and Rehabilitation Research Centre clinical research team (Ms Bernadette Shannon, Ms Kym Morris, Ms Christine Finn) for their clinical inputs and role as advanced General Movements Assessment raters.

Dr Benfer conceptualized the study, acquired funding, acquired the data, oversaw analysis and interpretation of the data including drafting of the manuscript, and has directly accessed and verified the underlying data reported in the manuscript; Drs Novak, Morgan, Whittingham, and Khan conceptualized the study; Dr Ware is the lead biostatistician and he conceptualized the study and oversaw all aspects related to the data analysis; Dr Bell and Oftedal conceptualized the nutritional aspects of the study; Dr Bandaranayake had a substantial role in acquiring the data; Dr Salt conceptualized the vision aspects of the study; Drs Bhattacharya and Samanta, Mr Ghosh, Mr Chowdhury, Mr Moula, and Mr Maiti had a substantial role in acquiring the data; Mr had a substantial role in acquiring the data; Dr Tripathi critically monitored the study progress and adverse events in his role as data and safety monitor; Dr Boyd conceptualized the study, acquired funding, and oversaw analysis and interpretation of the data including critical revision of the manuscript, and has directly accessed and verified the underlying data reported in the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Clinical Trial Registration: This study is registered with the Australia and New Zealand Clinical Trials Registry (identifier, ACTRN12616000653460).

Data Sharing Statement: Deidentified individual participant data that underlie the results reported in this article will be available after publication of primary randomized control trial results to researchers submitting a methodologically sound proposal.

For full trial protocol, refer to Benfer et al 2018, BMJ Open25 

FUNDING: The LEAP-CP study is funded by grants from the Cerebral Palsy Alliance Australia, QEII Diamond Jubilee Endeavour scholarship, Commonwealth Government Australia (K.A.B.); Merchant Charitable Funding; Australian National Health and Medical Research Council Early Career Grant (K.A.B.) 1195602 and Investigator grant (R.N.B.).

CONFLICT OF INTEREST DISCLOSURES: The authors have no conflicts of interest to disclose.

BSID-III

Bayley Scales of Infant Development, 3rd edition

CA

corrected age

CDW

community disability worker

CP

cerebral palsy

DASS

Depression Anxiety and Stress Scale

GMFCS

Gross Motor Function Classification System

HA

Health Advice (program)

HINE

Hammersmith Infant Neurologic Examination

HOME

Home Observation for Measurement of the Environment

LEAP-CP

Learning Through Everyday Activities for Parents of Infants at Risk for Cerebral Palsy

LMIC

low-middle income country

MD

mean difference

PDMS-2

Peabody Developmental Motor Scales, 2nd edition

PEDI-CAT

Pediatric Evaluation of Disability Inventory-Computer Adaptive Test

PMT

Poverty Measurement Tool

PSOC

Parenting Sense of Competence Scale

RCT

randomized controlled trial

1
Bax
M
,
Goldstein
M
,
Rosenbaum
P
, et al
;
Executive Committee for the Definition of Cerebral Palsy
.
Proposed definition and classification of cerebral palsy, April 2005
.
Dev Med Child Neurol
.
2005
;
47
(
8
):
571
576
2
Novak
I
,
Morgan
C
,
Adde
L
, et al
.
Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment
.
JAMA Pediatr
.
2017
;
171
(
9
):
897
907
3
Morgan
C
,
Fetters
L
,
Adde
L
, et al
.
Early intervention for children aged 0 to 2 years with or at high risk of cerebral palsy: international clinical practice guideline based on systematic reviews
.
JAMA Pediatr
.
2021
;
175
(
8
):
846
858
4
Gladstone
M
.
A review of the incidence and prevalence, types and aetiology of childhood cerebral palsy in resource-poor settings
.
Ann Trop Paediatr
.
2010
;
30
(
3
):
181
196
5
Jahan
I
,
Muhit
M
,
Hardianto
D
, et al
.
Epidemiology of cerebral palsy in low- and middle-income countries: preliminary findings from an international multi-centre cerebral palsy register
.
Dev Med Child Neurol
.
2021
;
63
(
11
):
1327
1336
6
Benfer
KA
,
Jordan
R
,
Bandaranayake
S
,
Finn
C
,
Ware
RS
,
Boyd
RN
.
Motor severity in children with cerebral palsy studied in a high-resource and low-resource country
.
Pediatrics
.
2014
;
134
(
6
):
e1594
1602
7
Juneja
M
,
Jain
R
,
Singhal
S
,
Mishra
D
.
Availing services for developmental disabilities: parental experiences from a referral center in developing country
.
Indian J Pediatr
.
2012
;
79
(
9
):
1213
1217
8
Al Imam
MH
,
Jahan
I
,
Das
MC
, et al
.
Rehabilitation status of children with cerebral palsy in Bangladesh: findings from the Bangladesh Cerebral Palsy Register
.
PLoS One
.
2021
;
16
(
5
):
e0250640
9
Serel Arslan
S
,
Demir
N
,
Karaduman
AA
.
Effect of a new treatment protocol called Functional Chewing Training on chewing function in children with cerebral palsy: a double-blind randomised controlled trial
.
J Oral Rehabil
.
2017
;
44
(
1
):
43
50
10
Batra
M
,
Sharma
VP
,
Batra
V
,
Malik
GK
,
Pandey
RM
.
Neurofacilitation of Developmental Reaction (NFDR) approach: a practice framework for integration / modification of early motor behavior (Primitive Reflexes) in cerebral palsy
.
Indian J Pediatr
.
2012
;
79
(
5
):
659
663
11
Chaturvedi
SK
,
Rai
Y
,
Chourasia
A
, et al
.
Comparative assessment of therapeutic response to physiotherapy with or without botulinum toxin injection using diffusion tensor tractography and clinical scores in term diplegic cerebral palsy children
.
Brain Dev
.
2013
;
35
(
7
):
647
653
12
Inal
Ö
,
Serel Arslan
S
,
Demir
N
,
Tunca Yilmaz
Ö
,
Karaduman
AA
.
Effect of Functional Chewing Training on tongue thrust and drooling in children with cerebral palsy: a randomised controlled trial
.
J Oral Rehabil
.
2017
;
44
(
11
):
843
849
13
McConachie
H
,
Huq
S
,
Munir
S
,
Ferdous
S
,
Zaman
S
,
Khan
NZ
.
A randomized controlled trial of alternative modes of service provision to young children with cerebral palsy in Bangladesh
.
J Pediatr
.
2000
;
137
(
6
):
769
776
14
Sığan
SN
,
Uzunhan
TA
,
Aydınlı
N
,
Eraslan
E
,
Ekici
B
,
Calışkan
M
.
Effects of oral motor therapy in children with cerebral palsy
.
Ann Indian Acad Neurol
.
2013
;
16
(
3
):
342
346
15
Guimarães
EL
,
Tudella
E
.
Immediate effect of training at the onset of reaching in preterm infants: randomized clinical trial
.
J Mot Behav
.
2015
;
47
(
6
):
535
549
16
Nascimento
AL
,
Toledo
AM
,
Merey
LF
,
Tudella
E
,
Soares-Marangoni
DA
.
Brief reaching training with “sticky mittens” in preterm infants: randomized controlled trial
.
Hum Mov Sci
.
2019
;
63
:
138
147
17
Soares
DA
,
van der Kamp
J
,
Savelsbergh
GJ
,
Tudella
E
.
The effect of a short bout of practice on reaching behavior in late preterm infants at the onset of reaching: a randomized controlled trial
.
Res Dev Disabil
.
2013
;
34
(
12
):
4546
4558
18
Valizadeh
L
,
Sanaeefar
M
,
Hosseini
MB
,
Asgari Jafarabadi
M
,
Shamili
A
.
Effect of early physical activity programs on motor performance and neuromuscular development in infants born preterm: a randomized clinical trial
.
J Caring Sci
.
2017
;
6
(
1
):
67
79
19
Zhang
Y
,
Lyu
T
,
Hu
X
,
Shi
P
,
Cao
Y
,
Latour
JM
.
Effect of nonnutritive sucking and oral stimulation on feeding performance in preterm infants: a randomized controlled trial
.
Pediatr Crit Care Med
.
2014
;
15
(
7
):
608
614
20
Asadollahpour
F
,
Yadegari
F
,
Soleimani
F
,
Khalesi
N
.
The effects of non-nutritive sucking and pre-feeding oral stimulation on time to achieve independent oral feeding for preterm infants
.
Iran J Pediatr
.
2015
;
25
(
3
):
e809
21
Lyu
T-c
,
Zhang
Y-x
,
Hu
X-j
,
Cao
Y
,
Ren
P
,
Wang
Y-j
.
The effect of an early oral stimulation program on oral feeding of preterm infants
.
International Journal of Nursing Sciences
.
2014
;
1
(
1
):
42
47
22
Younesian
S
,
Yadegari
F
,
Soleimani
F
.
Impact of oral sensory motor stimulation on feeding performance, length of hospital stay, and weight gain of preterm infants in NICU
.
Iran Red Crescent Med J
.
2015
;
17
(
7
):
e13515
23
Nair
MK
,
Philip
E
,
Jeyaseelan
L
,
George
B
,
Mathews
S
,
Padma
K
.
Effect of Child Development Centre model early stimulation among at risk babies--a randomized controlled trial
.
Indian Pediatr
.
2009
;
46
(
Suppl
):
s20
s26
24
Carlo
WA
,
Goudar
SS
,
Pasha
O
, et al
;
Brain Research to Ameliorate Impaired Neurodevelopment-Home-Based Intervention Trial Committee
;
the National Institute of Child Health and Human Development Global Network for Women’s and Children’s Health Research Investigators
.
Randomized trial of early developmental intervention on outcomes in children after birth asphyxia in developing countries
.
J Pediatr
.
2013
;
162
(
4
):
705
712.e3
25
Benfer
KA
,
Novak
I
,
Morgan
C
, et al
.
Community-based parent-delivered early detection and intervention programme for infants at high risk of cerebral palsy in a low-resource country (learning through Everyday Activities with Parents [LEAP-CP]): protocol for a randomised controlled trial
.
BMJ Open
.
2018
;
8
(
6
):
e021186
26
Romeo
DM
,
Cioni
M
,
Palermo
F
,
Cilauro
S
,
Romeo
MG
.
Neurological assessment in infants discharged from a neonatal intensive care unit
.
Eur J Paediatr Neurol
.
2013
;
17
(
2
):
192
198
27
Morgan
C
,
Novak
I
,
Dale
RC
,
Guzzetta
A
,
Badawi
N
.
GAME (Goals - Activity - Motor Enrichment): protocol of a single blind randomised controlled trial of motor training, parent education and environmental enrichment for infants at high risk of cerebral palsy
.
BMC Neurol
.
2014
;
14
:
203
28
Ramey
CT
,
Sparling
JJ
,
Ramey
SL
.
Abecedarian: The Ideas, the Approach, and the Findings
.
Sociometrics Corporation
;
2012
29
Haley
SM
,
Coster
WJ
,
Dumas
HM
,
Fragala-Pinkham
MA
,
Moed
R
.
PEDI-CAT Version 1.4.0: Development, Standardisation and Administration Manual
.
Trustees of Boston Universtiy
;
2011
30
Lovibond
S
,
Lovibond
P
.
Manual for the Depression, Anxiety and Stress Scales
. 2nd ed.
Psychology Foundation
;
1995
31
Law
M
,
Baptiste
S
,
Carswell
A
,
McColl
M
,
Polatajko
H
,
Pollock
NA
.
COPM 5th Edition: Canadian Occupational Performance Measure
.
Distributed Product
;
2014
32
Folio
MR
,
Fewell
RR
.
Peabody Developmental Motor Scales
. 2nd ed.
Pearson
.
2000
33
Bayley
N
.
Bayley Scales of Infant and Toddler Development
. 3rd ed.
Psychological Corporation
;
2006
34
Sonksen
PM
,
Petrie
A
,
Drew
KJ
.
Promotion of visual development of severely visually impaired babies: evaluation of a developmentally based programme
.
Dev Med Child Neurol
.
1991
;
33
(
4
):
320
335
35
World Health Organization
.
UNICEF. WHO Child Growth Standards and the Identification of Severe Acute Malnutrition in Infants and Children: A Joint Statement by the World Health Organization and the United Nations Children’s Fund
.
WHO Press
;
2009
36
Caldwell
BM
,
Bradley
RH
.
Home Observation for Measurement of the Environment
.
University of Arkansas at Little Rock
;
1984
37
Johnston
C
,
Mash
EJ
.
A measure of parenting satisfaction and efficacy
.
J Clin Child Psychol
.
1989
;
18
(
2
):
167
175
38
Boyd
RN
,
Jordan
R
,
Pareezer
L
, et al
.
Australian cerebral palsy child study: protocol of a prospective population based study of motor and brain development of preschool aged children with cerebral palsy
.
BMC Neurol
.
2013
;
13
:
57
39
Bhuiya
A
,
Mahmood
SS
,
Rana
AK
,
Wahed
T
,
Ahmed
SM
,
Chowdhury
AMR
.
A multidimensional approach to measure poverty in rural Bangladesh
.
J Health Popul Nutr
.
2007
;
25
(
2
):
134
145
40
Spittle
AJ
,
Treyvaud
K
,
Doyle
LW
, et al
.
Early emergence of behavior and social-emotional problems in very preterm infants
.
J Am Acad Child Adolesc Psychiatry
.
2009
;
48
(
9
):
909
918
41
Badawi
N
,
Watson
L
,
Petterson
B
, et al
.
What constitutes cerebral palsy?
Dev Med Child Neurol
.
1998
;
40
(
8
):
520
527
42
Smithers-Sheedy
H
,
Badawi
N
,
Blair
E
, et al
.
What constitutes cerebral palsy in the twenty-first century?
Dev Med Child Neurol
.
2014
;
56
(
4
):
323
328
43
Palisano
R
,
Rosenbaum
P
,
Walter
S
,
Russell
D
,
Wood
E
,
Galuppi
B
.
Development and reliability of a system to classify gross motor function in children with cerebral palsy
.
Dev Med Child Neurol
.
1997
;
39
(
4
):
214
223
44
Cans
C
;
Surveillance of Cerebral Palsy in Europe
.
Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of cerebral palsy in Europe (SCPE)
.
Dev Med Child Neurol
.
2000
;
42
(
12
):
816
824
45
Dumas
HM
,
Fragala-Pinkham
MA
,
Rosen
EL
,
Lombard
KA
,
Farrell
C
.
Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) and Alberta Infant Motor Scale (AIMS): validity and responsiveness
.
Phys Ther
.
2015
;
95
(
11
):
1559
1568
46
Morgan
C
,
Novak
I
,
Dale
RC
,
Guzzetta
A
,
Badawi
N
.
Single blind randomised controlled trial of GAME (Goals - Activity - Motor Enrichment) in infants at high risk of cerebral palsy
.
Res Dev Disabil
.
2016
;
55
:
256
267
47
Eliasson
AC
,
Nordstrand
L
,
Ek
L
, et al
.
The effectiveness of Baby-CIMT in infants younger than 12 months with clinical signs of unilateral-cerebral palsy; an explorative study with randomized design
.
Res Dev Disabil
.
2018
;
72
:
191
201
48
Holmström
L
,
Eliasson
AC
,
Almeida
R
, et al
.
Efficacy of the Small Step Program in a randomized controlled trial for infants under 12 months old at risk of cerebral palsy (CP) and other neurological disorders
.
J Clin Med
.
2019
;
8
(
7
):
1016
49
Hielkema
T
,
Hamer
EG
,
Boxum
AG
, et al
;
L2M 0-2 Study Group
.
LEARN2MOVE 0-2 years, a randomized early intervention trial for infants at very high risk of cerebral palsy: neuromotor, cognitive, and behavioral outcome
.
Disabil Rehabil
.
2020
;
42
(
26
):
3752
3761
50
Hoagwood
KE
,
Cavaleri
MA
,
Serene Olin
S
, et al
.
Family support in children’s mental health: a review and synthesis
.
Clin Child Fam Psychol Rev
.
2010
;
13
(
1
):
1
45
51
Babatunde
F
,
MacDermid
J
,
MacIntyre
N
.
Characteristics of therapeutic alliance in musculoskeletal physiotherapy and occupational therapy practice: a scoping review of the literature
.
BMC Health Serv Res
.
2017
;
17
(
1
):
375
52
Fairweather
GC
,
Lincoln
M
,
Ramsden
R
,
Bulkeley
K
.
Parent engagement and therapeutic alliance in allied health teletherapy programs
.
Health Soc Care Community
.
2022
;
30
(
2
):
e504
e513
53
Tröster
H
,
Brambring
M
.
Early motor development in blind infants
.
Journal of Applied Developmental Psychology
.
1993
;
14
(
1
):
83
106
54
Palmer
FB
,
Shapiro
BK
,
Wachtel
RC
, et al
.
The effects of physical therapy on cerebral palsy. A controlled trial in infants with spastic diplegia
.
N Engl J Med
.
1988
;
318
(
13
):
803
808
55
Laar
ME
,
Marquis
GS
,
Lartey
A
,
Gray-Donald
K
.
Reliability of length measurements collected by community nurses and health volunteers in rural growth monitoring and promotion services
.
BMC Health Serv Res
.
2018
;
18
(
1
):
118
56
Pencharz
PB
.
Protein and energy requirements for ‘optimal’ catch-up growth
.
Eur J Clin Nutr
.
2010
;
64
(
Suppl 1
):
S5
S7
57
Karlsson
O
,
Kim
R
,
Sarwal
R
,
James
KS
,
Subramanian
SV
.
Trends in underweight, stunting, and wasting prevalence and inequality among children under three in Indian states, 1993-2016
.
Sci Rep
.
2021
;
11
(
1
):
14137
58
Whittingham
K
,
Sanders
MR
,
McKinlay
L
,
Boyd
RN
.
Parenting intervention combined with acceptance and commitment therapy: a trial with families of children with cerebral palsy
.
J Pediatr Psychol
.
2016
;
41
(
5
):
531
542
59
Ohgi
S
,
Fukuda
M
,
Akiyama
T
,
Gima
H
.
Effect of an early intervention programme on low birthweight infants with cerebral injuries
.
J Paediatr Child Health
.
2004
;
40
(
12
):
689
695
60
Hielkema
T
,
Boxum
AG
,
Hamer
EG
, et al
.
LEARN2MOVE 0-2 years, a randomized early intervention trial for infants at very high risk of cerebral palsy: family outcome and infant’s functional outcome
.
Disabil Rehabil
.
2020
;
42
(
26
):
3762
3770
61
Hayles
E
,
Harvey
D
,
Plummer
D
,
Jones
A
.
Parents’ experiences of health care for their children with cerebral palsy
.
Qual Health Res
.
2015
;
25
(
8
):
1139
1154
62
Callanan
J
,
Signal
T
,
McAdie
T
.
What is my child telling me? Reducing stress, increasing competence and improving psychological well-being in parents of children with a developmental disability
.
Res Dev Disabil
.
2021
;
114
:
103984
63
Gorter
JW
,
Ketelaar
M
,
Rosenbaum
P
,
Helders
PJ
,
Palisano
R
.
Use of the GMFCS in infants with CP: the need for reclassification at age 2 years or older
.
Dev Med Child Neurol
.
2009
;
51
(
1
):
46
52

Supplementary data